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ABSTRACT 
 
GENETIC AND EPIGENETIC MODIFIERS OF C9ORF72 EXPRESSION IN 
NEURODEGENERATIVE DISEASE 
 
Christopher P. Cali 
 
Edward B. Lee 
 
Repeat expansion mutations in the gene C9orf72 are the most common cause of the fatal 
neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration 
(FTD). The molecular mechanisms that contribute to these diseases are still not fully understood. 
In this dissertation, we explore mechanisms associated with repeat expansions in C9orf72 that 
alter gene expression and contribute to disease. In chapter 2, we develop a novel method of 
targeted DNA methylation in order to study how epigenetic changes in C9orf72 expansion 
carriers contribute to disease pathways. We find that C9orf72 promoter hypermethylation is 
sufficient to reduce gene expression and induce heterochromatin silencing of this locus in ALS 
patient derived cells. We also uncover a link between DNA damage repair pathways and DNA 
methylation where a double strand break in CpG islands can promote DNA methylation. 
Furthermore, we have taken advantage of these findings to develop and optimize a novel 
targeted DNA methylation method that utilizes homology directed repair for precise methylation 
editing in the absence of off-target effects. In chapter 3, we ask whether intermediate length 
repeat expansions in C9orf72 are associated with a different neurodegenerative disease, 
corticobasal degeneration (CBD). CBD shares similar clinical symptoms with Parkinson’s disease 
but exhibits distinct tau pathology in neurons and glial cells. We find that intermediate C9orf72 
repeat expansion carriers (17-30 repeats) are three times more likely to develop CBD than those 
with smaller repeats. While full expansion carriers with ALS/FTD tend to have reduced C9orf72 
expression, we show that intermediate expansion carriers actually have increased C9orf72 
mRNA and protein levels. This increase in C9orf72 expression drives aberrant gene expression 
profiles in vesicle trafficking, stress response and autophagy pathways. Furthermore, we find that 
vi 
 
autophagy initiated by nutrient starvation is deficient in cells that over-express C9orf72. In sum, 
this thesis contributes a novel method of targeted DNA methylation to the research community 
and shows how DNA methylation alters expression of a disease relevant gene. This work also 
highlights how variable lengths of the repeat expansion in C9orf72 can lead to distinctive 
underlying molecular mechanisms and ultimately drive risk for different neurodegenerative 
diseases. 
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Chapter 1: Introduction 
Genetics of amyotrophic lateral sclerosis and frontotemporal degeneration  
 
Amyotrophic lateral sclerosis (ALS) and frontotemporal degeneration (FTD) are 
fatal neurodegenerative diseases with clinical and genetic overlap
1,2
. ALS is a progressive 
motor neuron disease selectively affecting both upper and lower motor neurons resulting 
in muscle atrophy and death generally within 2-4 years after onset
3
. FTD is a disease that 
preferentially affects the frontal and temporal cortex in which cortical neurons degenerate 
resulting in language, memory and behavioral deficits
4
. Although age of onset for ALS 
and FTD are similar (usually 50-60 years old), patients with FTD can live 10+ years after 
disease onset
5
. Additionally, ALS and FTD clinical symptoms can co-occur in the same 
patient
3
.  These diseases can be classified by whether they have a known genetic etiology. 
For instance, familial or hereditary disease is typically caused by a recognized genetic 
mutation that adheres to classic Mendelian inheritance patterns. Sporadic forms of 
ALS/FTD, on the other hand, usually do not have known disease-linked mutations and 
typically do not follow defined inheritance patterns in families, although they can still 
have a genetic component
6–8
.  
Sporadic ALS accounts for up to 90% of total ALS cases
6
. To date, several loci 
have been reproducibly associated with sporadic ALS, but these explain only a small 
percentage of the underlying genetic etiology
9
. These include an association within an 
intron of UNC13A, a gene involved in neurotransmitter realease
10–12
. Another association 
has been identified near the gene SARM1
11,13
, the protein product of which has been 
shown to promote axonal degeneration in mice
14
. These associations occur in non-coding 
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regions, and thus it is still not clear whether the closest genes to the associated 
polymorphisms are actually those underlying ALS risk. Two loci that do have rare amino 
acid changes in sporadic ALS patients, however, have recently been identified
11,12
. These 
include polymorphisms found in C21orf2 and KIF5A
11,12
. The function of C21orf2 
however, is not yet clear, but it may be involved in DNA repair pathways and cilia 
development
15,16
. KIF5A is a microtubule-associated molecular motor that is known to 
function in neuronal pathways such as synaptic transmission, and knockout of the gene in 
mice leads to epilepsy
17
. Thus, KIF5A represents an interesting candidate gene to explore 
further. Finally, all major ALS genome-wide association studies identified variants in a 
region on chromosome 9, which were later found to be a risk haplotype associated with 
the carriers of a mutation in the gene C9orf72
11–13,18
.  Mutations in C9orf72 will be 
discussed in more detail in later sections. 
As for sporadic FTD, there have only been a few identified genetic risk factors, 
perhaps due the clinical and neuropathological heterogeneity of this disease
19–23
. The first 
identified association was with TMEM106B
19,23
, a membrane bound protein involved in 
lysosomal pathways
24
. Variants in TMEM106B were later implicated as disease modifiers 
in patients with familial FTD caused by GRN or C9orf72 mutations, thus connecting this 
genetic association with known disease mechanisms
25–27
. Other associations include 
variants near the HLA locus and a locus encompassing RAB38 and CTSC
21
. Additionally, 
variants in the ALS risk gene UNC13A have also been associated with FTD
2
. Several 
other associations have been reported but have not yet been validated in replication 
cohorts
28
. 
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Much progress has been made in determining genetic causes of familial ALS and 
FTD. Approximately 30 genes have been implicated in familial ALS, with the most 
frequent being mutations in C9orf72 and SOD1
29
. SOD1, which encodes copper-zinc 
superoxide dismutase, is an antioxidant enzyme that normally functions to reduce cellular 
superoxide levels to prevent free radical induced damage
30
. There are over 160 known 
mutations in SOD1, which account for 20% of all familial ALS cases
6
. Mutated SOD1 
protein forms insoluble aggregates in mitochondria that can be detected in patient spinal 
cord and may be the cause of neurotoxicity
31,32
.  Mutations in TARDBP, which encodes 
the RNA binding protein TDP-43, are also a cause of familial ALS and account for 
approximately 4% of familial ALS cases
33
. Mutations in TARDBP are notable because 
TDP-43 protein aggregates are a hallmark of sporadic ALS as well
34
.  Mutations in 
another RNA binding protein, FUS¸ is also linked to familial ALS and these mutations 
account for 3% of cases
6
. While rare, mutations in FUS and TARDBP implicate RNA 
metabolism as a key disease pathway in ALS
35
. 
The most frequently mutated genes that cause familial FTD include C9orf72, 
MAPT, and GRN
22
.  MAPT mutations, which encode the microtubule associated protein 
tau, account for 10-20% of familial cases
36
. Carriers of MAPT mutations have unique 
pathology in that they develop hyper-phosphorylated tau aggregates in the brain rather 
than TDP-43
31
. Tau aggregation is thought to be neurotoxic and is implicated in a host of 
other neurodegenerative diseases such as Alzheimer’s disease, corticobasal degeneration, 
Pick’s disease and progressive supranuclear palsy37. Mutations in GRN account for 5-
20% of familial FTD cases and result in TDP-43 brain pathology
36
. GRN mutations are 
thought to cause disease through loss of function of the progranulin protein, which 
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normally may be involved in the inflammatory response to neuronal damage
38
. There are 
also additional very rare mutations that cause FTD in genes such as VCP, TBK1, 
CHMP2B and TARDBP
36
. Most of these rare mutations also lead to TDP-43 pathology
22
.  
Identification of the C9orf72 repeat expansion mutation 
 
The most recently discovered and the most common mutation underlying both 
ALS and FTD (~30-50% of familial cases) occurs in the gene C9orf72
6
. This locus was 
first identified as contributing to ALS and FTD by linkage analysis of large families that 
showed an autosomal dominant inheritance pattern for ALS and/or FTD
39,40
. The 
susceptibility region on chromosome nine was further refined by genome-wide 
association studies in European populations, which led to the discovery of a 42 variant 
haplotype block spanning three genes that segregated with disease risk
41,42
. The casual 
gene and mutation, which consisted of a G4C2 microsatellite repeat expansion in C9orf72, 
was discovered in 2011
43,44
. The hexanucleotide repeat expansion sequence can repeat 
hundreds to thousands of times within the first intron of the gene
45
. Several studies have 
attempted to find genetic or epigenetic factors that may determine whether a C9orf72 
expansion carrier develops ALS verses FTD, but these have largely been 
inconclusive
46,47
.  To better understand the underlying pathogenic mechanisms of the 
C9orf72 repeat expansion, it’s important to consider related neurodegenerative diseases 
that are also caused by microsatellite repeat expansions. 
Microsatellite repeat expansions and disease 
 
 Microsatellite repeat expansion diseases are a group of hereditary 
neurodegenerative diseases caused by repetitive DNA elements that form large 
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expansions within exons, introns or untranslated regions
48
.  The mechanism of 
pathogenesis is often determined by the gene in which the expansion lies and the 
sequence of the expansion itself (Figure 1.1).  
 
Figure 1.1: Microsatellite repeat expansions and neurodegenerative disease. Genomic 
locations and proposed mechanisms of repeat expansions that cause neurodegenerative diseases. 
Expansions can occur in the 5’UTR, exon, intron or 3’UTR of over 20 genes. Repetitive RNA 
from repeat expansions can lead to neuronal toxicity via sequestration of RNA binding proteins or 
through toxic protein species. Additionally, repeat expansions that are close to the transcription 
start site (TSS) can reduce expression of the gene in which they reside. Adapted from Liu, Cali and 
Lee (2017)
35
; used under the Creative Commons Attribution License.  
 
For instance, the CAG trinucleotide repeat in Huntington’s disease occurs within the first 
exon of HTT, where it is translated into aggregation-prone polyglutamine protein, leading 
to a toxic gain of function disease mechanism
49
. On the other hand, a CGG repeat in the 
5’ untranslated region of FMR1 causes fragile X syndrome via epigenetic silencing and 
reduction of the normal FMRP protein
50
. When a repeat expansion occurs within an 
intron, however, the molecular pathogenesis is not as apparent. In Friedreich’s ataxia, for 
example, an intronic GAA repeat reduces transcription of FXN and leads to 
neurodegeneration via loss of function mechanisms
51,52
. However, an intronic CCTG 
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repeat in CNBP is thought to cause myotonic dystrophy type 2 via a toxic RNA gain of 
function mechanism
53
.  Thus, when the intronic hexanucleotide repeat expansion was 
discovered within C9orf72, both a toxic gain of function mechanism and a loss of 
function mechanism were proposed (Figure 1.2)
43,44
.   
 
Figure 1.2: Proposed mechanisms of C9orf72 repeat expansion pathogenesis. A) An intronic repeat 
expansion in C9orf72 (red box) is thought to cause disease through either loss of function or gain of 
function mechanisms. C9orf72 has 3 mRNA isoforms (arrows represent transcription start sites) which give 
rise to protein isoforms A and B. Only protein isoform A is detectable in human samples. B) Loss of 
function mechanisms include decreased mRNA levels from expansion carriers (left panel) and increased 
DNA methylation of the C9orf72 promoter (right panel), leading to haploinsufficiency of the C9orf72 
protein. C) C9orf72 is involved in endosomal/lysosomal pathways. Interaction between C9orf72 and 
autophagy initiation components ULK/ATG101 has been observed (left). Additionally, C9orf72 can bind 
CARM1 to facilitate lysomal biogenesis (middle). C9orf72 also interacts with p62 to regulate stress granule 
formation (right). D) Gain of function mechanisms include pathology derived from the repeat expansion 
sequence such as RNA foci (left) and dipeptide repeat (DPR) aggregates (right). E) Repeat RNA foci 
sequester RNA binding proteins and alter RNA splicing and nuclear transport (left). DPR aggregates are 
thought to bind elongation initiation factor 3 (eIF3) and the ribosomal subunits, leading to global 
translational dysregulation (right). 
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Loss of function mechanisms of C9orf72 repeat expansions 
 
In the years since the discovery of the C9orf72 repeat expansion, there have been 
efforts to define the molecular mechanisms of C9orf72 expansion mediated 
neurodegeneration.  One proposed hypothesis was a loss function mechanism in which 
reduced C9orf72 gene product resulted in haploinsufficiency of the normal protein 
because reduced levels of C9orf72 mRNA and protein have been detected in repeat 
expansion carriers
43,44,54
. Bioinformatic analysis of the primary amino acid sequence 
revealed that C9orf72 is related to a class of proteins called Rab guanine exchange 
factors, which are important regulators of vesicle trafficking
55
. Furthermore, the loss of 
function hypothesis is supported by the finding that C9orf72 does regulate vesicle 
trafficking and autophagy in neuronal cell lines
56
 and knockout in zebrafish results in 
motor deficits
57
. However, the loss of function model does not fully account for the 
results of studies using C9orf72 knockout mouse models.  
In one mouse study, global deletion of C9orf72 resulted in several inflammatory 
phenotypes including splenomegaly, lymphadenopathy and altered microglial and 
macrophage function
58
. These mice, however, did not have neurodegenerative or 
behavioral phenotypes that recapitulate ALS/FTD symptoms and lived a normal 
lifespan
58
.  In another study, C9orf72 knockout again caused splenomegaly as well as 
inflammation that is consistent with autoimmune disease but no overt signs of 
neurodegeneration
59
. In this study, however, complete knockout of C9orf72 severely 
reduced lifespan, despite these mice being generated by the same methods as the 
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previously mentioned study
59
. A possible explanation for the difference in lifespan 
between the two studies could be due to environmental factors such as diet, stress levels 
or handling differences between the different institutions where the studies were 
conducted. Another knockout mouse study also reported an autoimmune phenotype 
consisting of myeloid expansion, T-cell activation and production of autoantibodies but 
no neurodegeneration or ALS/FTD related phenotypes and normal lifespan
60
. All of the 
C9orf72 knockout mouse models, however, exhibit aberrant immune system phenotypes 
in only the homozygous knockout mouse but not in the heterozygous mouse
58–60
. Given 
that almost all C9orf72 repeat expansion carriers are heterozygous for the expanded 
allele
61
, the disease relevance of C9orf72 bi-allelic knockout mouse models are 
questionable. Indeed, recent studies with novel antibodies or using mass spectrometry to 
better quantify protein levels have shown that C9orf72 protein levels are only reduced by 
~20-40% in ALS/FTD patients
62,63
.  Furthermore, the effects seen in global C9orf72 
knockout mice do not demonstrate how compromised immune system function would 
interact with neuronal cells that are prone to degenerate in these diseases. To answer this 
question, an additional mouse study used a conditional allele to knockout C9orf72 
expression in only neurons and glial cells at embryonic day 10.5 onward
64
. This study 
had the advantage of examining C9orf72 function in only disease relevant cell types and 
after early developmental stages. The neuron/glial specific C9orf72 knockout mouse had 
no signs of neurodegeneration and no indication of aberrant inflammation, suggesting 
that the autoimmune effects observed in whole body knockouts were likely due to 
C9orf72 functions in hematopoietic cells
64
. Overall, the animal models do show that the 
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C9orf72 protein has biological functionality that is worth exploring, but its relevance to 
neurodegenerative disease is not yet clear. 
C9orf72 protein function and autophagy  
 
The exact function of C9orf72 has been difficult to define, but it’s been suggested 
that C9orf72 functions broadly in vesicle trafficking pathways such as the endosomal-
lysosomal system and autophagy 
65
. The C9orf72 protein contains a region homologous 
to the DENN (differentially expressed in neoplastic versus normal) domain, which allows 
interaction with Rab GTPases to allow exchange of GDP with GTP and thus provide the 
energy required for intracellular vesicle movement (Figure 1.3)
66
 .  
 
Figure 1.3: Proposed functions of C9orf72 protein. C9orf72 is a DENN domain containing 
protein that may function as a guanine exchange factor to provide energy for Rab GTPases, which 
are involved in numerous vesicle trafficking pathways including intracellular trafficking, vesicle 
secretion, stress granule assembly and autophagy. C9orf72 occurs in a complex with WDR41, 
SMCR8 and various Rab GTPase proteins. 
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Recent studies have shown that C9orf72 is capable of interacting with numerous Rab 
GTPases (including Rab1a, Rab8, Rab39 and Rab7L1) that function at different steps of 
the endo-lysosomal and autophagy pathways
67–71
. It is also well documented that C9orf72 
occurs in a complex with the proteins SCMR8 and WD41
72
, and this complex interacts 
with the ULK1 autophagy initiation complex
67,69,73,74
. However, whether C9orf72 
normally promotes autophagy induction or reduces autophagic flux is still not 
resolved
67,69,74,75
. This issue is complicated by the observation that C9orf72 functions 
differently in response to nutrient stress than it does under normal conditions
71,74
 and also 
has other related functions such as regulation of stress granules via autophagy
76,77
. The 
complexity of C9orf72 function may be due to its ability to interact with many Rab 
GTPases, which then can carry out diverse functions within these vesicle trafficking sub-
pathways
78
. For instance, C9orf72 has been demonstrated to act as guanine exchange 
factor (GEF) for Rab8 and Rab39
68
, but its closest homolog, folliculin, is a GTPase-
activating protein  (GAP)
79
. GAPs and GEFs both regulate Rab GTPases that are 
important for vesicle trafficking, but they do so through opposite mechanisms. GEFs 
exchange GDP for GTP, thus activating the Rab GTPase for downstream signaling, 
whereas GAPs stimulate GTP hydrolysis and inactivation of the target Rab GTPase
79
. 
Given the homology to folliculin, it is possible that C9orf72 could have both GAP and 
GEF activity depending on the target, although this has not yet been shown 
experimentally. Additionally, the Rab GTPases that are targets of C9orf72 may change 
depending on the cell type, conditions or stressors present. Thus, further study is needed 
to define how C9orf72 functions in stress conditions and how the autophagy functions of 
C9orf72 interact with the repeat expansion associated pathology. 
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Gain of function mechanisms of C9orf72 repeat expansions 
 
The other major hypothesis for understanding the molecular mechanisms of 
C9orf72 repeat expansions is that neurodegeneration results from toxic RNA and protein 
species that are derived from the repeat expansion sequence
80
. Using fluorescent probes 
against the repeat RNA, RNA “foci” were first observed in the nucleus of cortex and 
spinal cord tissue from ALS/FTD patients
43
 and have since been observed in numerous 
animal and cellular models
81–85
. Repeat RNA have been shown to bind and sequester 
RNA binding proteins such as those involved in splicing and nuclear transport
86–88
. 
Splicing factors that are possibly disrupted by the mutant RNA include hnRNP H and 
SRSF2
86–88
, whereas nuclear transport defects may be due to sequestration of ALYREF 
and RanGAP1 by repeat expanded RNA
86,89
. This in turns leads to alterations in RNA 
splicing pathways as well as defective nuclear transport of RNA
87,90–93
. This RNA 
dysregulation model is attractive because defects in other RNA binding proteins such as 
FUS and TDP-43 are established mechanisms of neurodegeneration
35
. 
Another pathological hallmark of C9orf72 expansion carriers is the presence of 
cytoplasmic protein aggregates that are generated from repeat RNA via the non-canonical 
translation pathway known as Repeat Associated Non-AUG translation
94–96
. These 
aggregates consist of chains of dipeptides which are translated from all reading frames of 
the G4C2 repeat sequence in both the sense and antisense direction
97
. These dipeptide 
repeat proteins (DPRs) are toxic in several model systems and proposed mechanisms of 
neurodegeneration include impaired global translation pathways, impaired RNA 
biogenesis, deficiencies in stress response pathways, and altered nucleocytoplasmic 
transport
98–103
. Finally, all C9orf72 repeat expansion carriers develop cytoplasmic TDP-
12 
 
43 aggregates, which is a hallmark of sporadic ALS and most forms of FTD
34
.  TDP-43 
normally resides in the nucleus, where it regulates RNA splicing, transport and stability
34
.  
In ALS/FTD, TDP-43 is lost from the nucleus and aggregates in the cytoplasm, resulting 
in thousands of gene expression changes in pathways such as RNA processing, 
nucleocytoplasmic transport, histone processing, and DNA damage
104
. Thus, the toxic 
nature of these three major pathologies (RNA foci, DPR and TDP-43) are thought to 
underlay the gain of function model.  
More experimental evidence for the gain of function hypothesis comes from 
mouse models of C9orf72 expansion carriers that were generated either by Adeno 
Associated Virus (AAV) delivery of G4C2 repeats or by insertion of the human repeat 
expansion sequence via Bacterial Artificial Chromosome (BAC)
105
. Over-expression of 
G4C2 repeats using AAV resulted in neurodegeneration, cognitive defects, RNA foci, and 
both DPR and TDP-43 pathology
84
. AAV delivery of only a DPR encoding sequence 
without the G4C2 RNA also induced motor and cognitive deficits in mice along with 
characteristic pathology
106
, suggesting that DPRs alone are sufficient to cause ALS/FTD-
like phenotypes. However, both of these methods drive pathology through over-
expression at levels that are higher than observed in human disease
84,106
. Mice generated 
using the human gene within a BAC construct, which represents a more physiological 
model, also had characteristic RNA foci and DPR pathology
85,107–109
. While there were 
differences between studies in the observed phenotypes, two studies reported cognitive 
and motor defects in these mouse models
108,109
 and one reported sparse TDP-43 
pathology
109
. Thus, expression of the repeat construct alone, without loss of normal 
C9orf72 protein, is sufficient to recapitulate many features of ALS/FTD in mice.  
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In humans, however, it’s not yet clear which pathology (e.g. RNA foci, DPRs or 
TDP-43 aggregation) are most responsible for driving neurodegeneration. TDP-43 
aggregation is seen in regions of neurodegeneration in almost all ALS and FTD cases, 
except for familial cases caused by rare mutations
34
. This suggests that TDP-43 
aggregation is linked to neurodegenerative processes. Indeed, TDP-43 pathology 
correlates more closely with neurodegeneration in C9orf72 expansion carriers than DPR 
pathology does
110
. However, there have been several reports that FTD patients, including 
some that died prematurely before end stage disease, can develop neurodegeneration in 
the absence of TDP-43 pathology
111,112
. This has led to the idea that RNA foci and DPR 
pathology may be an early event in disease progression, with TDP-43 aggregation 
occurring later. Increased levels of DPR pathology has been reported to correlate with 
earlier age of onset in both ALS and FTD cases
113
, suggesting that DPR aggregation may 
initiate disease progression. Of note, ALS cases have never been found without TDP-43 
pathology, suggesting that the contribution of these pathologies may differ between ALS 
verses FTD
114
. Future studies will need to clarify how pathology derived from the repeat 
expansion interacts with TDP-43 pathology and which of these is necessary for disease 
progression. 
A final consideration is that both a loss of function and gain function mechanism 
together may contribute to pathogenesis. A study using induced motor neurons from ALS 
patients suggests that a reduction in C9orf72 protein levels causes vesicle trafficking and 
lysomal defects that make neurons more susceptible to DPR aggregates from the repeat 
expansion
115
. This model presents a two hit hypothesis, where a loss of C9orf72 
endosomal trafficking functions combine with toxicity from the repeat expansion 
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sequence. Although this concept is not currently supported by data from available mouse 
models, it is an interesting idea that should be further explored in future studies.  
Intermediate repeat expansions in C9orf72 
 
 Repeat expansions in C9orf72 that cause ALS and FTD are usually hundreds to 
thousands of units long, with an average length of approximately 1400-1600 G4C2 repeat 
units in cerebellum
45
. Repeat expansions this large are almost fully penetrant, as 
approximately 96% of carriers will develop either ALS or FTD before age 80
45,116
. The 
minimum repeat number to develop ALS/FTD, however, has not been fully established. 
There have been reports of small repeat sizes as low as 40-65 repeats in patients with 
FTD
117–119
. However, there are issues that make accurate repeat sizing difficult including 
somatic mosaicism within individuals, differences depending on the tissue collected and 
technical challenges in accurately sizing a GC rich repetitive sequence
45,117
. A case report 
of a cognitively normal individual with a repeat size of 30-40 units in cerebellum showed 
that this length was enough to induce RNA foci and DPR pathology, but not TDP-43 
pathology or clinical disease
120
. This was in contrast to a report indicating that a carrier 
with 38 repeats in several brain regions developed ALS with TDP-43 pathology and 
sparse DPR pathology
121
. Finally, another case report shows that an individual with an 
average of 70 repeats (with some larger expansions in different brain regions) did not 
develop clinical disease by age 90
122
. Thus, it appears that there is inter-patient variability 
with regards to the minimum repeat length necessary to cause ALS/FTD, perhaps due to 
differences in the genetic background or the degree of somatic mosaicism between 
individuals. In general, it seems that repeat expansions less than 30 units do not cause 
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ALS/FTD, whereas 30-70 repeats may represent a gray zone that depends on other 
genetic and/or environmental factors. The majority (~70-80%) of non-diseased 
individuals carry repeats of 2-8 units, whereas ~5% of the global population has repeat 
sizes greater than 10 units
123
. Whether intermediate repeat expansions that are too small 
to contribute to ALS/FTD but larger than normal (e.g. 10-30 units) are a risk factor for 
other diseases remains an open question. 
 Several studies have examined the prevalence of intermediate C9orf72 expansions 
in other neurodegenerative diseases. Intermediate expansions were completely absent in 
Alzheimer’s disease119, but several studies reported small numbers of intermediate repeat 
carriers with Parkinson’s Disease (PD)124,125. Interestingly, a follow up study that 
investigated C9orf72 repeat length in only autopsy confirmed PD cases did not find any 
intermediate or full expansions, suggesting discrepancies between clinically and 
neuropathologically defined cohorts
126
. Finally, a large global meta-analysis of C9orf72 
repeat length in PD patients found a significant but very minor association of PD with 
intermediate length alleles (≥ 17 repeats) and concluded that the risk of developing PD 
for intermediate carriers was negligible
123
. Thus, it is still not clear whether intermediate 
repeat expansions in C9orf72 spanning 10-30 units are a risk factor for neurodegenerative 
disease. Additionally, a recent study with a very small cohort examined C9orf72 repeat 
sizes in autoimmune diseases and found a significant association between systemic lupus 
erythematosus and intermediate repeats (9-30 units)
127
. While autoimmunity has been 
implicated in C9orf72 knockout mice
59
, additional follow up studies will be necessary to 
determine if there’s any biological significance of C9orf72 intermediate repeat 
expansions in this context.  
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Epigenetic alterations in microsatellite repeat expansion diseases 
 It is also important to consider epigenetic mechanisms of pathogenesis associated 
with microsatellite repeat expansion disorders. DNA methylation is a covalent 
modification of cytosine that is typically associated with transcriptional inhibition and is 
carried out by several DNA methyltransferase enzymes (DNMTs)
128,129
.  One important 
function of DNA methylation is promotion of genome stability by silencing of repetitive 
elements
130,131
. DNA methylation patterns are known to change during aging and in the 
context of neurodegenerative disease
132
. Indeed, aberrant DNA methylation is a common 
feature of microsatellite repeat expansion diseases and has been associated with myotonic 
dystrophy, Friedreich’s ataxia and Fragile X syndrome 133–135. In the case of Fragile X, 
the main driver of disease seems to be a loss of FMR1 expression that is associated with 
DNA methylation of the upstream promoter
135
.  Thus, epigenetic alterations are important 
to understand the pathogenesis of repeat expansion mutations. 
Changes in DNA methylation are also observed in C9orf72 repeat expansion 
carriers. Approximately 33-36% of C9orf72 carriers gain DNA hypermethylation of the 
promoter region, which is normally unmethylated in non-diseased individuals
47,136–139
. 
Promoter hypermethylation was not significantly different between ALS and FTD 
patients, but interestingly, hypermethylation correlates with longer survival in FTD 
patients
47
. Hypermethylation also correlates with reduced RNA foci and DPR abundance 
in patient tissue and patient derived cells
137
, indicating that C9orf72 promoter 
methylation may be protective in the setting of the repeat expansion. Additionally, FTD 
patients with promoter hypermethylation have reduced verbal recall decline over time 
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and reduced grey matter volume loss as measured by MRI
140
. Why DNA 
hypermethylation seems to be beneficial in FTD patients with the repeat expansion but 
not ALS patients is an unresolved question. One possibility, as discussed previously, is 
that TDP-43 pathology is driving neurodegeneration in ALS patients, whereas FTD 
pathogenesis is may be more connected to repeat expansion pathology that is dependent 
on C9orf72 expression. Additionally, why only a subset of patients develop 
hypermethylation is also not clear. Studies to date have only applied correlative analysis 
to study DNA methylation in C9orf72 carriers. To better understand these basic questions 
and to define the causal mechanisms associated with DNA hypermethylation of C9orf72, 
there is a need for disease models that accurately represent DNA hypermethylation as is 
observed in C9orf72 repeat expansion carriers. Furthermore, an ideal model would be 
generated via targeting DNA methylation in a controlled and specific fashion to the 
C9orf72 promoter in patient derived cells. Such epigenetic editing experiments would 
allow generation of isogenic cell lines that do not suffer from confounding factors due to 
genetic background.  
Methods of Epigenetic Editing 
 
 In the past decade, novel epigenetic editing tools have been developed that take 
advantage of DNA binding proteins fused to epigenetic effector enzymes. These include 
zinc finger proteins, TALE proteins and dead Cas9 proteins fused to DNA or histone 
modifiers
141
. These fusion protein epigenetic editing tools have helped to define basic 
cellular mechanisms
142–149
 and have been applied as potential therapeutics in diseases 
with epigenetic alterations
150,151
. For targeted DNA methylation, a dead Cas9 enzyme 
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fused to the catalytic domain of DNA methyltransferase 3a (dCas9-DNMT3a) was the 
first tool generated using CRISPR/cas9
152
. CRISPR/cas9 based epigenetic editing 
methods are attractive alternatives to zinc finger and TALE proteins due the low cost and 
ease of multiplexing with guide RNAs (gRNAs) against various target loci
141
. However, a 
major issue has emerged with dCas9 based DNA methylation editing tools concerning 
specificity. Recent studies have observed that dCas9-DNMT3a tools can induce 
thousands of off-target methylation changes
153–155
. Numerous off-target effects have also 
been observed with dCas9 fused to cytosine base editing enzymes
156
. A possible 
explanation of these off-target effects is that Cas9 is able to bind DNA sequences with 
only a few base pairs of homology to the gRNA sequence, but requires more extensive 
homology to initiate DNA cleavage
157,158
.  Thus, dCas9 fusion proteins that only require 
binding for DNA modification seem to initiate immensely more off-target changes than 
traditional Cas9 applications that rely on DNA double strand breaks
159
. A newer DNA 
methylation editing system has attempted to alleviate the off-target effects of dCas9 
fusion proteins by using a modular system, called the SunTag system, to recruit DNMT3a 
to the locus where dCas9 is bound
155
. The advantage of this system is that dCas9 is not 
directly fused to DNMT3a and the amount of DNMT3a recruitment can be manipulated 
by the expression levels of an antibody that binds the SunTag sequence
155
. However, this 
system requires generation of multiple plasmids to target a single locus and the levels of 
off-target effects are dependent on the amount of DNMT3a recruitment
155
. Thus, optimal 
levels of the antibody encoding plasmid will need to be experimentally determined for 
each application in order to prevent off-target target methylation. 
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DNA methylation and DNA repair pathways 
 
While almost all available tools for epigenetic editing involve fusion protein 
constructs, there is actually considerable evidence that DNA double strand break repair 
pathways can alter DNA methylation. Numerous studies have demonstrated that DNMTs 
are recruited to double strand break sites
160–163
. Upon double strand break, DNA can be 
repaired either through the process of non-homologous end joining (NHEJ) or homology 
directed repair (HDR)
164
. NHEJ occurs during G1 phase of the cell cycle and involves 
recognition of the DNA break by the Ku complex, recruitment of the protein DNA-PKcs, 
generation of overhangs by Artemis and finally ligation and fill-in by DNA 
polymerases
164
. The polymerases used during NHEJ are error-prone, often resulting in 
insertions or deletions (indels) at the repaired site
164
. Alternatively, the break can be 
repaired using HDR, which is error free but occurs at lower frequency than NHEJ
165
. 
HDR is a complex process that involves resection of the broken DNA ends, invasion of 
the repair template and DNA synthesis using the repair template followed by ligation to 
complete the newly copied DNA
166
. 
 Several studies have utilized fluorescent reporter DNA constructs to interrogate 
whether DNA double strand breaks can induce DNA methylation. These studies show 
that upon double strand break repair via HDR, a subset of the repaired DNA becomes 
methylated, which leads to a reduction of reporter expression
167–170
. While there is some 
disagreement between studies, methylation of the exogenous construct following DNA 
repair appears dependent on DNMT1
167
, DNMT3a
169
 and UHRF1
169
, a protein 
responsible for DNMT1 recruitment to hemi-methylated DNA
171
. Additionally, a double 
strand break induced in a reporter construct that is repaired via NHEJ can also lead to 
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DNA methylation
172
. Thus, it seems that DNA methylation is acquired following double 
strand break regardless of the repair pathway that is utilized. 
Objectives and Hypotheses   
 
 The overall objectives of this dissertation were to better understand the genetic 
and epigenetic disease mechanisms underlying C9orf72 repeat expansions. In Chapter 2, 
we aimed to generate a novel targeted DNA methylation technique that takes advantage 
of the endogenous DNA double strand break repair pathways. We hypothesized that 
double stranded breaks in the promoter CpG island of C9orf72 would facilitate 
methylation near the break site. In the absence of repair template, the break would be 
repaired with NHEJ, which would lead to localized DNA methylation along with indels 
(Figure 1.4, left). In order to direct precise methylation editing, we asked whether an in 
vitro methylated repair template could be supplied such that during HDR the methylation 
marks would be copied from the exogenous repair template into the endogenous gene 
(Figure 1.4, right).  
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Figure 1.4: Proposed mechanisms of targeted DNA methylation via DNA double strand 
break repair pathways. Double strand breaks are induced in a CpG island via CRISPR/cas9. In 
the absence of repair template (left), the break is repaired via non-homologous end joining, 
resulting in recruitment of DNA methyltransferases (DNMTs) to the break site and introduction 
of localized DNA methylation. This pathway is also associated with insertions or deletions 
(indels) near the break site. In order to direct precise methylation editing, an in vitro CpG 
methylated template is provided (right) so that the break is repaired via homology directed repair. 
During repair, UHRF1 is recruited to hemi-methylated DNA, which then recruits DNMTs to copy 
methylation from the repair template into the endogenous sequence. 
 
This would lead to templated methylation and should avoid the numerous off-target 
effects observed with dCas9 fusion protein constructs. The final aim of chapter 2 was 
then to apply this method, termed Homology Assisted Repair Dependent Epigenetic 
eNgineering (HARDEN) to ALS/FTD patient derived cells with the C9orf72 repeat 
expansion in order to generate a disease model of epigenetic dysfunction that’s observed 
in patients. Using this model, we sought to directly test how DNA hypermethylation 
affects C9orf72 expression and downstream pathogenesis.  
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 In Chapter 3, we aimed to determine the genetic and molecular mechanisms of 
intermediate repeat expansions in C9orf72. Previous studies conflicted as to whether 
intermediate repeats contribute to other neurodegenerative diseases such as Parkinson’s 
disease (PD). We hypothesized that intermediate repeats in C9orf72 may be a risk factor 
instead for corticobasal degeneration (CBD), a neurodegenerative disease that shares 
clinical features with PD but has distinct pathological protein aggregates consisting of 
tau
173
. In this study, we also sought to determine how intermediate repeats may affect 
expression of C9orf72. We hypothesized that intermediate repeats may alter expression 
differently than full repeat expansions that cause ALS/FTD. Finally, we sought to 
uncover the molecular pathways that are affected in intermediate repeat carriers. 
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Chapter 2: Targeted DNA methylation of C9orf72 via endogenous DNA 
repair pathways 
 
This chapter has been adapted from following manuscript, which is currently in revision at 
Nucleic Acids Research, (Oxford University Press). Used under Creative Commons License 
 
“Targeted DNA methylation of the ALS/FTD gene C9orf72 via endogenous DNA damage repair 
pathways” by Christopher P Cali1, Daniel S Park1, and Edward B Lee1. 
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Abstract 
 
DNA methyltransferases (DNMTs) are thought to be involved in the cellular 
response to DNA damage, thus linking DNA repair mechanisms with DNA methylation. 
This study presents a novel method of targeted DNA methylation that utilizes 
endogenous DNA double strand break repair pathways and applies it to the 
neurodegenerative disease gene C9orf72. A double strand break induced by 
CRISPR/cas9 in the promoter of C9orf72 is sufficient to induce DNA methylation, and 
methylation can be precisely targeted through the process of homology directed repair 
(HDR) via delivery of an in vitro methylated exogenous repair template. Long 
methylated double stranded DNA templates induce more methylation than shorter 
templates and with higher efficiency than a dCas9-DNMT3a fusion protein construct.  
Genome-wide methylation analysis reveals no significant off-target methylation changes 
when inducing methylation via HDR, whereas the dCas9-DNMT3a fusion construct 
causes significant off-target methylation at over 67,000 sites. This method is applied to 
generate a patient derived iPSC model of amyotrophic lateral sclerosis and 
frontotemporal dementia (ALS/FTD) that exhibits stable DNA methylation patterns 
similar to those seen in patients. Using this model, it’s shown for the first time that DNA 
methylation of the 5’ regulatory region directly reduces C9orf72 expression and increases 
histone H3K9 tri-methylation levels.  
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Introduction 
 
 Methylation of cytosine is a chemical modification of DNA associated with a 
myriad of regulatory processes in the mammalian genome such as regulation of gene 
expression, stabilization of repeat elements, X-inactivation and maintenance of genomic 
integrity
128
. Alterations in DNA methylation are associated with numerous diseases, 
including cancer and neurodegenerative diseases such as those caused by expansion of 
microsatellite repeat elements
132
. Aberrant methylation of the C9orf72 promoter region 
has been observed in repeat expansion carriers with amyotrophic lateral sclerosis (ALS) 
and frontotemporal dementia (FTD)
47,137,139
. In these patients, neurodegeneration is 
caused by a repeat expansion in the first intron of C9orf72 which has been proposed to 
cause production of toxic RNA and protein pathologies in patient tissue
94
, patient derived 
cells
81–83,98
 and animal models
84,85,88
. Interestingly, hypermethylation of the promoter 
occurs in ~1/3 of patients and correlates with increased survival time, reduced neuronal 
loss and better verbal recall ability in FTD patients
47,140
. Thus, we hypothesize that 
hypermethylation in the context of C9orf72 repeat expansions is neuroprotective. 
However, to define causality between hypermethylation and disease pathology, there is a 
need to generate isogenic patient derived cell lines that accurately model this epigenetic 
aspect of ALS/FTD.  
  Current tools for targeted DNA methylation, such as the dead Cas9 (dCas9)–DNA 
methyltransferase (DNMT) fusion protein
152
, have several features that limit their utility 
for generation of epigenetic disease models. Recent studies have shown that the 
methylation editing tools, such as the dCas9-DNMT3a fusion protein, have numerous 
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off-target effects
153–155,174,175
, which may confound experiments or limit their use as 
therapeutic agents.  Another limitation with available tools is that these constructs are 
usually large and difficult to transfect into patient derived primary cells or deliver via 
gene therapy vectors for therapeutic purposes
176
 and they often require multiple gRNAs 
to achieve robust activity
152,174,175,177,178
. Additionally, DNA methylation changes made 
via the fusion protein constructs are often not maintained over numerous cell divisions at 
some loci,
148,152,153
 making it difficult to generate stably edited cell lines for disease 
modeling.  
 Due to these limitations, we sought to develop a novel method for epigenetic 
editing that has fewer off target effects and enables generation of cellular disease models. 
Development of this new system was based on the observation that endogenous DNMTs 
are rapidly recruited to double stranded DNA (dsDNA) breaks
160,161,163,168,169
. For 
example, when dsDNA breaks are induced in exogenous reporter DNA constructs, a 
subset of cells gain DNA methylation of the exogenous construct, leading to gene 
silencing
167–170
. Whether this acquired DNA methylation following break repair is unique 
to exogenously expressed DNA or also occurs at endogenous loci is not yet known. We 
sought to answer this question and furthermore to determine whether precise methylation 
editing could be carried out via the process of homology directed repair (HDR) by 
providing the cells with an in vitro generated repair template containing the methylation 
marks to be copied into the genome. To our knowledge, no previous study has shown that 
exogenous DNA methylation marks can be copied into an endogenous gene.  
This study demonstrates that double stranded DNA breaks can directly induce 
DNA methylation of the C9orf72 promoter and that methylation can be copied during 
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HDR. These findings suggest that we have developed a novel method for editing DNA 
methylation that takes advantage of the endogenous cellular repair machinery and does 
not require over-expression of a methyltransferase enzyme. We term this method 
Homology Assisted-Repair Dependent Epigenetic eNgineering (HARDEN) because 
stable methylation editing is achieved upon DNA repair via HDR. This method exhibited 
vastly fewer off-target effects than dCas9-DNMT3a fusion constructs and enables 
generation of stably methylated cell lines that model epigenetic alterations seen in 
neurodegenerative disease. 
 
Methods 
 
Plasmid and Repair template Generation 
CRISPR gRNAs were designed using Benchling software (http://benchling.com/) and 
cloned into pSpCas9(BB)-2A-Puro (PX459) V2.0 vector (Addgene, Cambridge, MA; 
Plasmid #62988))  for HARDEN experiments or pdCas9-DNMT3A-PuroR (ANV) 
(Addgene Plasmid #71684) and pdCas9-DNMT3A-PuroR_v2 (Addgene Plasmid 
#74407) as previously described
179
. Single stranded oligonucleotide templates including 
methylated oligonucleotides were synthesized by Integrated DNA Technologies, Inc. 
(Coralville, Iowa). The non-homologous oligonucleotide template is homologous against 
the unrelated gene EMX1. Sequences of gRNAs and templates are provided in 
Supplemental Tables 2.1 and 2.2. Double stranded DNA templates were made by PCR 
amplification of the target region using Q5 High Fidelity polymerase (New England 
Biolabs, Ipswich, MA) according to the manufacturer’s protocol. 250ng of purified PCR 
products were A-tailed in a reaction containing 0.25mM dATP, 1.5mM MgCl2, 1X 
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Buffer II and 5U Amplitaq polymerase (Applied Biosystems, Foster City, CA) for 30 
minutes at 70⁰ C. A-tailed PCR products were ligated into pGEM-T Easy vector 
(Promega, Madison, WI) and transformed into NEB Turbo competent cells (New 
England Biolabs) according to the manufacturer’s protocol. For introduction of PAM 
mutations, site directed mutagenesis was carried out using the QuickChange XL kit 
according to the manufacturer’s protocol (Agilent Technologies, Santa Clara, CA). Non-
homologous dsDNA templates consisted of the pGEM-T Easy vector without the 
C9orf72 homologous region. For methylation of plasmid repair templates, 20ug of 
plasmid DNA was methylated in a 100ul reaction containing 50U of M.SssI CpG 
Methyltransferase (New England Biolabs), 640 µM SAM, 50 mM NaCl, 10 mM Tris-
HCl (pH 7.9) and 10 mM EDTA for 4 hours at 37⁰C. Enzyme was inactivated for 20 
minutes at 65⁰ C and then plasmid DNA was purified via phenol chloroform extraction 
followed by ethanol precipitation.  
 
Cell Culture and Transfection 
HEK293T cells were grown in DMEM high glucose + L-glutamine (Invitrogen, 
Carlsbad, CA) supplemented with 10% fetal bovine serum (Atlanta Biologicals, Flowery 
Branch, GA) and 1X Penicillin/Streptomycin (Invitrogen). For transfection of CRISPR 
components, 1μg Cas9/gRNA containing plasmid and 1μg repair template were co-
transfected into 12 well dishes using Fugene 6 (Promega) or Lipofectamine 3000 
(Invitrogen) with a 3:1 transfection to DNA ratio for 48 hours. For siRNA experiments, 
cells were transfected with 40nM siRNA using Lipofectamine 3000 (Invitrogen). For 
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time points longer than 2 days, puromycin selection was carried out at 1μg/mL for 3-4 
additional days. For clonal line isolation, cells were diluted to 1cell/well in 96 well plates 
7 days post transfection. DNA from clonal lines was isolated using QuickExtract Solution 
(Lucigen, Middleton, WI) according to manufacturer’s protocol and screened for repair 
with the template using PCR and restriction enzyme digest. Induced pluripotent cell line 
CS52iALS-n6A was obtained from Cedars Sinai and maintained in mTeSR1 media 
(Stem Cell Technologies, Vancouver, Canada) and grown on Matrigel matrix (Corning, 
Corning, NY) coated plates as previously described
81
.  For transfection of CRISPR 
components, 750ng Cas9/gRNA plasmid + 750ng repair template was co-transfected into 
12 well dishes using Viafect reagent (Promega) with a 4:1 transfection to DNA ratio for 
48 hours. 0.5ug/mL puromycin was used for selection of transfected iPSCs.  
 
Methylation sensitive restriction enzyme digest qPCR  
Methylation sensitive restriction enzyme digest quantitative PCR (qPCR) was carried out 
as previously described
137
. Genomic DNA was extracted using DNeasy Extraction kit 
(Qiagen) and qPCR was carried out using FastStart Universal SYBR Green mastermix 
(Roche, Basel, Switzerland) on a StepOne Plus Real-Time PCR Machine (Life 
Technologies) using standard cycling. For measurement of methylation in samples 
transfected with 1.4kb double-stranded templates, a forward primer was used that anneals 
outside the repair template and the qPCR cycling conditions were modified (38 cycles, 
annealing temperature  61.5 ⁰C, 1 min extension at 72⁰C) to increase specificity. % 
methylation was calculated using the formula 2^(Ct Mock - Ct Digest). Fold change over 
30 
 
controls was calculated for long amplicon qPCR because percent digest verses % 
methylation is not 1:1. See Supplemental Table 2.1 for primers.   
 
T7 Endonuclease Assay and HDR digest Assay 
A T7 endonuclease assay was used to measure mutation (indel +HDR) efficiency based 
on T7 digestion of mismatched DNA hybrids.  Genomic DNA was PCR amplified using 
Q5 hotstart polymerase (New England Biolabs), hybridized and digested with T7 
Endonuclease I (New England Biolabs) according to manufacturer’s protocol. To 
specifically measure HDR efficiency, 12ul of PCR product was digested with 8U SspI-
HF (New England Biolabs) in 1X Cutsmart buffer for 2 hours at 37⁰ C. Digest products 
were run on either 2% agarose gels for T7 assay or 8% polyacrylamide gels for HDR 
assay and stained with SYBR Gold (Invitrogen). Bands were quantified using 
GelAnalyzer 2010a software (http://www.gelanalyzer.com/index.html) using valley to 
valley background subtraction. For calculating T7 digest efficiency, we used the formula: 
% digest = 100 x (1 – (1- fraction cleaved)1/2) as described previously180. For the 
restriction enzyme HDR assay: % digest = (sum digested products) / (undigested + 
digested products). 
 
Bisulfite Cloning 
1ug of genomic DNA was bisulfite converted and cleaned up using the EpiTect Bisulfite 
Kit (Qiagen) according to manufacturer’s protocol. Bisulfite converted DNA (7.5% of 
total per reaction) was then PCR amplified using KAPA HiFi Uracil+ Readymix (Roche) 
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according to manufacturer’s protocol. PCR products were purified with Ampure XP 
beads (Beckman Coulter), A-tailed with Amplitaq polymerase (Applied Biosystems), 
ligated into pGEM Easy T vector (Promega) and transformed into NEB Turbo competent 
cells (New England Biolabs) as described above. Amplicons were sequenced at the 
University of Pennsylvania Sanger Sequencing core using the T7 promoter/primer. 
Bisulfite analysis was carried out using BISMA software
180
 and only sequences with 
>90% conversion rate were included in the analysis. 
 
Genome Wide Methylation Analysis 
Genome wide methylation analysis was carried out using the EPIC Array (Illumina, San 
Diego, CA), which measures CpG methylation at ~800,000 sites. Samples were 
transfected for 48hrs with either dCas9-DNMT3a-Puro, dCas9-DNMT3a-ANV-Puro or 
Cas9-Puro + 190bp methylated template and gRNA targeting C9orf72. Samples were 
puromycin selected for 48 hours and genomic DNA was extracted 4 days post 
transfection. Samples were then bisulfite converted and processed using the Infinium 
Methylation EPIC Kit (illumina) by the Center for Applied Genomics at Children’s 
Hospital of Philadelphia. Data was analyzed in R using the Bioconductor package 
ChAMP
181
. Data was normalized with the beta-mixture quantile normalization method 
(BMIQ) and significantly differentially methylated probes were called using default 
parameters with the Benjamini-Hochberg procedure for false discovery rate adjustment. 
 
RNA Expression from iPSCs 
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Cells were harvested via Accutase (Stem Cell Technologies), pelleted, washed in PBS 
and resuspended in 350ul RLT buffer (Qiagen). Lysates were homogenized via pipetting 
and vortexing and RNA was extracted using the RNeasy kit (Qiagen) with on-column 
DNAse digest for 15 minutes at room temperature. 1μg of RNA was converted to cDNA 
using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
according to manufacturer’s protocol. cDNA was diluted tenfold and 4μl was used in a 
qPCR reaction with 2X FastStart Universial SYBR Green master mix (Roche) and 
0.25μM of each primer. qPCR was run with default cycling conditions on a StepOne Plus 
qPCR machine (Applied Biosystems). Relative expression was calculated using the delta 
delta Ct method by normalizing to housekeeping genes (ACTB, GPS). 
 
Chromatin Immunoprecipitation 
Edited iPSC clonal lines were cross-linked with 1% formaldehyde (37⁰ C, 10 minutes) 
and quenched with 125μM glycine. Cells were lysed (0.5% SDS, 10mM EDTA, 50mM 
Tris/HCl, pH 8) and sonicated on high power for 30 cycles using a Bioruptor 300 
(Diagenode, Denville, NJ). 1μg of chromatin was incubated overnight at 4⁰ C with 
Protein A Dynabeads (Life Technologies) and 5μl of antibody against H3K9me3 (Cell 
Signaling #13969) or IgG. Beads were washed with buffers of increasing stringency 
(Low salt, high salt, lithium chloride and 1X TE buffer) and DNA was eluted in buffer 
containing 1% SDS. RNA and protein were digested using RNAse A (Thermo Scientific) 
and proteinase K (Promega). DNA was purified using PCR purification kit (Qiagen) and 
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eluted in 200μl EB Buffer (Qiagen). 4μl purified DNA was inputted into a qPCR reaction 
as described above and percentage of input was calculated for each sample.  
 
 
Results 
 
Targeted DNA methylation using oligonucleotide repair templates 
 As DNMTs are recruited to DNA damage sites, we tested the hypothesis that a 
dsDNA break induced by Cas9 in an endogenous locus would result in increased DNA 
methylation.  HEK293T cells were transfected with a plasmid encoding for Cas9 with or 
without a gRNA specific to the C9orf72 promoter, together with a negative control single 
stranded oligonucleotide non-homologous DNA repair template.  Methylation was 
measured at a CpG site in the promoter region (Figure 2.1A) using a previously 
developed methylation sensitive restriction enzyme digest qPCR assay (MSRE-qPCR)
137
. 
This assay provides a quantitative measure of methylation of the C9orf72 promoter based 
on resistance of DNA to digestion by the methylation-sensitive HhaI enzyme and the 
primers used anneal outside the repair templates and thus can only amplify genomic 
DNA.  In the absence of gRNA, there were no measurable changes in methylation 
(Figure 2.1B), regardless of the presence or absence of various exogenous 
oligonucleotide repair templates.  In contrast, cells transfected with plasmids encoding 
Cas9, a gRNA targeting C9orf72 and the non-homologous repair template, exhibited an 
increase in promoter methylation in unselected cells (Figure 2.1B). Endogenous dsDNA 
breaks in this context are repaired mainly through non-homologous end joining 
(NHEJ)
164
.  Thus, a double strand break alone, in the absence of HDR, appears to induce 
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methylation of the C9orf72 promoter.  Methylation in this condition, however, was 
transient and dissipated after only five days in culture (Figure 2.1F). 
To test the hypothesis that DNA methylation can be copied from an exogenous 
repair template into the genome, HEK293T cells were then transfected with Cas9, gRNA 
targeted to the C9orf72 promoter and a single stranded oligonucleotide homologous 
repair template that was either unmethylated or methylated at every CpG dinucleotide (10 
sites total). Cells that received an unmethylated homologous template had a reduction in 
methylation compared to those transfected with the non-homologous template, and cells 
transfected with a methylated repair template showed increased methylation when 
compared to those transfected with the unmethylated template (Figure 2.1B). These 
results suggest that methylation of the exogenous repair template promotes methylation 
of the endogenous C9orf72 promoter. 
To measure NHEJ, a T7 endonuclease assay was used that digests mismatched 
PCR amplicons
180
. As a readout of HDR, a 2bp mutation was made in the repair template 
that creates an SspI restriction enzyme site (Figure 2.1A). NHEJ efficiency was similar 
between conditions and was consistently higher than HDR rates as expected (Figure 
2.1C-E), which perhaps underlies the observation that methylation in the non-
homologous template condition was the highest (as NHEJ is more frequent than HDR). 
The methylation associated with the methylated oligonucleotide repair template was 
slightly more stable, but still returned to baseline eight days post transfection (Figure 
2.1G).  Thus, NHEJ and HDR were associated with transient DNA methylation of the 
C9orf72 promoter following Cas9-mediated DNA damage. 
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To test the precision of HDR dependent methylation, we designed an 
oligonucleotide repair template with a single methylated CpG site, corresponding to the 
HhaI restriction enzyme site used in our methylation assay (Figure 2.1H). If methylation 
of this single CpG site was copied via HDR, it should block HhaI digestion with similar 
efficiency as the fully methylated template.  Indeed, HEK293T cells transfected with 
Cas9 and the single methylated CpG repair template had similar HhaI resistance as cells 
transfected with Cas9 and the fully methylated template (Figure 2.1H). Thus, a single 
stranded oligonucleotide template with a single methylated CpG site appears to be 
sufficient to target methylation to the C9orf72 promoter in a transient manner. 
 
Longer double stranded templates improve methylation efficiency and stability 
  While it appeared that methylation of the endogenous C9orf72 promoter could be 
induced upon HDR with a methylated exogenous oligonucleotide repair template, 
methylation appeared to be relatively inefficient and transient.  To enhance DNA 
methylation efficiency and stability, we tested the ability to introduce DNA methylation 
via HDR using longer double stranded DNA (dsDNA) repair templates. In vitro 
methylated dsDNA repair templates with 190bp (10 CpGs), 600bp (35 CpGs) and 1.4kb 
(53 CpGs) total homology to the C9orf72 promoter were generated (Supplemental Table 
3.S2) with mutations of the CRISPR PAM site to disallow repeat cutting of edited loci 
and to monitor HDR efficiency (Figure 2.2A). Unmethylated versus fully methylated 
repair templates were co-transfected with plasmids encoding CRISPR-Cas9 components 
into HEK239T cells. After four days, methylation was tested using a long amplicon 
MSRE-qPCR assay that only amplifies genomic DNA and not the repair templates. 
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Indeed, longer dsDNA templates induced more CpG methylation in a length dependent 
manner, with the longest repair template group showing more than two fold higher 
methylation levels than the shortest template group (Figure 2.2B). 
HDR efficiency was monitored using restriction digests of genomic DNA PCR 
products to detect mutations of the PAM recognition site that is present in the DNA 
repair templates. HDR efficiency of the different templates does not explain the observed 
differences in DNA methylation, as the shortest 190bp methylated repair template 
resulted in the most HDR but the least amount of DNA methylation (Figure 2.1B and 
Supplemental Figure 2.1). Moreover, the methylation status of the repair template did not 
appear to affect HDR efficiency (Supplemental Figure 2.2). Additionally, upon 
comparing the 190bp dsDNA repair template versus the single stranded oligonucleotide 
repair template, there was a non-significant increase in methylation associated with the 
dsDNA template (Supplemental Figure 2.2), suggesting that DNA strandedness does not 
account for the increase in methylation efficiency when using longer dsDNA repair 
templates.  Together, these results suggest that the length of the dsDNA repair template 
was the main factor that allowed for more efficient induction of DNA methylation. 
Next, the HARDEN method of targeted DNA methylation was compared to the 
previously developed dead Cas9 (dCas9) DNMT3a catalytic domain fusion protein 
construct
152
.  HEK293T cells were transfected with either Cas9+gRNA to C9orf72 and 
the 1.4kb dsDNA methylated repair template or the dCas9-DNMT3a construct with the 
same gRNA. As negative controls, cells were transfected with catalytically inactive 
DNMT-dCas9 fusion enzyme (dCas9-DNMT3a-ANV) or Cas9 plasmid without gRNA. 
In control groups, there was very little detectable methylation using MSRE-qPCR (Figure 
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2.2C). Robust levels of methylation were induced using either dCas9-DNMT3a or 
HARDEN; however, the HARDEN method induced ~50% more methylation and thus 
has slightly improved efficiency at this locus.  Notably, the same gRNA was used for 
both methods (Figure 2.2C). These results indicate that HARDEN may be an effective 
alternative method for targeted DNA methylation of the C9orf72 locus. 
Next, we tested whether methylation copied from a long dsDNA repair template is stably 
maintained after cell division, as this is important for targeted methylation editing 
applications.  Cells were transfected with Cas9 and gRNA targeting C9orf72 and either 
non-homologous repair template, unmethylated 1.4kb dsDNA repair template or 
methylated 1.4kb dsDNA repair template. As a control, cells transfected with Cas9 
plasmid without gRNA and with a non-homologous repair template were used. 
Methylation was measured by MSRE-qPCR at the indicated days post transfection. Cells 
that were transfected with methylated template maintained higher methylation levels than 
controls and remained stable throughout the 30 day time course (Figure 2.2D). 
Additionally, cells transfected with either the unmethylated or methylated 1.4kb repair 
templates were sub-cloned and screened for clonal lines that underwent HDR using the 
repair template via PCR and restriction enzyme digest (Figure 2.2E-F). Clones were 
passaged from single cells and analyzed ~5 weeks after transfection of CRISPR 
components and repair template. 9 out of 13 clones (69.2%) that were repaired with the 
methylated template acquired >10% methylation, compared to only 1 clone out of 16 
(6.3%) repaired with the unmethylated template (Supplemental Figure 2.3) as measured 
by MSRE-qPCR. Furthermore, all three clones that were repaired with the methylated 
template on both alleles became hypermethylated, with levels of methylation ranging 
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from 60-80% by both MSRE-qPCR and bisulfite sequencing of cloned amplicons (Figure 
2.2G-H). Thus, repair with methylated dsDNA repair templates promotes stable and 
dense methylation of the C9orf72 promoter.  
 
DNA Methylation is acquired via Homology Directed Repair 
 Next, the underlying mechanisms of HARDEN were explored to better 
understand the efficiency and required proteins for this process. The first question tested 
was what percentage of DNA molecules that are repaired with an exogenous methylated 
repair template actually undergo copying of methylation into the endogenous DNA. To 
address this question, a ~1200bp dsDNA repair template was designed to insert a 12bp 
mutation that would serve as a primer site to specifically amplify genomic DNA in which 
the mutation is incorporated via HDR (Figure 2.3A). HEK293T cells were transfected 
with CRISPR components and either an unmethylated or methylated version of this 
template. Bisulfite PCR of genomic DNA from transfected cells showed that the mutation 
specific PCR only amplified DNA from cells that were co-transfected with repair 
template (Figure 2.3B). Bisulfite sequencing of these cloned amplicons revealed that 
DNA repaired with the unmethylated template was rarely methylated, with ~5% of total 
CpGs methylated (Figure 2.3C-D) and only 1/27 amplicons having at least 20% 
methylation (Figure 2.3E). In comparison, DNA repaired with the methylated template 
was methylated at greater than 50% of CpGs throughout much of the amplicon(Figure 
2.3C-D) and had 24/31 highly methylated amplicons (Figure 2.3E). Moreover, bisulfite 
sequencing revealed that DNA methylation in the setting of HDR did not induce DNA 
methylation of the last 3’ CpG site within the bisulfite amplicon (CpG site #22, Figure 
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2.3C).  This is notable because the repair template covered the entire bisulfite amplicon 
except this 3’ CpG site, consistent with our hypothesis that DNA methylation is copied in 
a templated manner.  Thus, repair with a methylated homologous template facilitates 
methylation of the endogenous locus.  
Next, siRNA knockdowns of DNA methyltransferase enzymes were carried out to 
determine which DNMTs are required for methylation during this process. siRNA against 
either DNMT1, DNMT3a, DNMT3b, and the DNMT1 recruiting factor UHRF1 were 
first transfected into HEK293T cells, and 24 hours later, the CRISPR components and a 
methylated 1.4kb repair template were introduced. Methylation was measured by MSRE-
qPCR following an additional 48 hour incubation period. Knockdown of any of these 
proteins resulted in ~40-50% decrease in the amount of methylation acquired using 
HARDEN (Supplemental Figure 2.4). These results indicate that there may be non-
redundant roles for DNMTs and UHRF1 for the establishment and/or maintenance of 
methylation during DNA repair. 
 
Genome wide methylation of epigenetically edited cells 
 The previous results demonstrate that HARDEN can be a useful method for 
targeted methylation of C9orf72. Next, the potential genome-wide off target effects of 
HARDEN were explored and compared to the dCas9-DNMT3a catalytic domain fusion 
protein construct. Because HARDEN utilizes both the 20bp gRNA sequence and a 
homologous repair template to induce methylation, we hypothesized that HARDEN 
would be highly specific for the targeted locus. To test this, HEK293T cells were 
transfected with either the dCas9-DNMT3a construct, or CRISPR components and 
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methylated repair template (C9orf72+ Meth). As negative controls, catalytically inactive 
dCas9 enzyme (dCas9-DNMT3a-ANV) or Cas9 plasmid without gRNA but with a 
methylated repair template (No gRNA+Meth) were used. Non-transfected cells were also 
included as an additional control to ensure transfection did not perturb global DNA 
methylation. Genome-wide methylation analysis was measured using genome wide 
arrays that detect DNA methylation at ~800,000 CpG sites. No statistically significant off 
target effects were detected using the HARDEN method (Figure 2.4A). This is in contrast 
to the dCas9-DNMT3a fusion construct which resulted in massive off target methylation 
(67,246 sites with p < 0.05) when compared to the dCas9-DNMT3a-ANV construct 
(Figure 2.4B). These off-target effects are not attributable to the gRNA, as the same 
gRNA was used for both the dCas9-DNMT3a group and the HARDEN group. When 
looking at the raw methylation values across the genome, there was no difference in 
methylation at lowly methylated sites between non-transfected cells or cells transfected 
with HARDEN components (Figure 2.4C). However, cells transfected with dCas9-
DNMT3a showed a pronounced gain in methylation at lowly methylated sites compared 
to non-transfected cells and cells transfected with dCas9-DNMT3a-ANV  (Figure 2.4D). 
These results suggest that HARDEN is a highly specific method for DNA methylation 
editing and confirms previous findings that dCas9-DNMT3a fusion proteins have 
massive global off-target effects. 
 
Editing of Methylation in ALS patient derived iPSCs 
  ALS and FTD patients with the C9orf72 repeat expansion can exhibit promoter 
hypermethylation, which is thought to contribute to transcriptional repression of the 
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C9orf72 gene
137
. To model this aspect of ALS/FTD, HARDEN was applied to previously 
characterized patient derived iPSCs
81
 harboring the repeat expansion but with limited 
C9orf72 promoter methylation (Supplemental Figure 2.5). IPSCs were transfected with 
CRISPR components and either unmethylated and or methylated 1.4kb dsDNA 
templates. Clonal lines were isolated and tested for incorporation of the PAM mutation 
via HDR using restriction enzyme digestion of PCR amplicons (Figure 2.5A). 
Methylation of edited clones was measured using MSRE-qPCR. Targeted methylation of 
iPSCs was slightly less efficient than in HEK293Ts, but stably methylated clones were 
obtained with methylation levels of ~20-50% (Figure 2.5B). DNA methylation levels 
were confirmed by bisulfite sequencing of cloned amplicons (Figure 2.5D). Additionally, 
chromatin immunoprecipitation (ChIP) was performed on clonal iPSCs  using an 
antibody against the repressive histone mark H3K9 trimethylation (Figure 2.5C). iPSCs 
that gained DNA methylation also gained H3K9 trimethylation, indicating a switch to a 
repressive chromatin state, and this increase was specific for the C9orf72 locus (Figure 
2.5C, Supplemental Figure 2.6). Finally, RNA was extracted from these edited iPSCs and 
mRNA levels of the major C9orf72 isoforms were measured via RT-qPCR (Figure 2.5E). 
Methylated iPSC clones had reduced mRNA levels by ~50%, with the largest effect seen 
for variant 3 (Figure 2.5H), which has a transcription start site closest to the targeted CpG 
island. These results indicate that hypermethylation of the C9orf72 promoter CpG island 
does indeed cause a reduction of C9orf72 expression, confirming previous reports that 
were based only on correlative analysis
47,137
. Thus, HARDEN can be used to generate a 
disease model of aberrant methylation and allows for defining the direct effect of DNA 
methylation on gene expression at this locus. 
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Discussion 
This study highlights a novel method for targeted DNA methylation and applies it 
to generate a cellular disease model. In doing so, several new findings about the interplay 
between DNA damage repair pathways and DNA methylation were explored. First, these 
results suggest that a targeted double strand break can induce DNA methylation of an 
endogenous locus. Previous studies have demonstrated that repair of dsDNA breaks in a 
GFP-based reporter construct can lead to DNA methylation following repair by either 
NHEJ
172
 or HDR
167–170
. This study demonstrates that this process also occurs at an 
endogenous gene, although methylation acquired following NHEJ is not maintained 
through cell division and is lost within 5 days in culture. The reduction in methylation 
observed following NHEJ is consistent with passive demethylation, with ~50% reduction 
each day. These results indicate that localized DNA methylation may serve as a transient 
marker of dsDNA breaks, perhaps to prevent transcription and promote stability of 
potentially mutagenized DNA. 
Another finding is that methylation appears to be copied from either a single or 
double stranded DNA template through the process of HDR, including from 
oligonucleotides harboring a single methylated CpG site. This level of specificity could 
be useful to study the effect of a particular CpG site on transcription factor binding. 
Longer double stranded templates seem to be more efficient at inducing methylation than 
short single stranded oligonucleotide templates and methylation induced via dsDNA 
templates can be stably maintained over numerous cell divisions in both HEK293T cells 
and iPSCs. Our results suggest that template length is more important than strandedness 
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for inducing methylation, as there is only a small, non-significant increase in efficiency 
between 190bp ssOligo templates and the corresponding 190bp dsDNA template. In 
contrast, there are more sizeable observed differences in efficiency between 190bp, 
600bp and 1.4kb dsDNA templates. It is not clear whether this effect is due to the overall 
increase in the number of methylated CpGs or if the longer templates include key CpG 
sites necessary for stable methylation of the C9orf72 promoter. There is evidence, for 
example, that specific transcription factor binding sites may be more important than the 
total number of methylated CpGs for determining promoter methylation state
182
.  
Knockdown of DNA methyltransferase enzymes revealed that both de novo (DNMT3a 
and 3b) and maintenance methyltransferases (DNMT1) as well as UHRF1 are required 
for efficient methylation using HARDEN.  These enzymes have previously been shown 
to assemble at double strand DNA break sites
160,168,169
, and UHRF1 is thought to be 
important for double strand break repair in addition to its role in maintenance 
methylation
183
. Thus, it appears that an interplay of these enzymes and cofactors function 
in concert to promote methylation during DNA damage repair, although they may 
function in different repair sub-pathways .  
HARDEN was also compared to the dCas9-DNMT3a fusion protein, and it 
appears that HARDEN has slightly better on-target efficiency at C9orf72 than the dCas9-
DNMT3a construct. Importantly, HARDEN has no detectable off-target effects, whereas 
the dCas9-DNMT3a fusion protein induces tens of thousands of off-target methylation 
changes. While only the off-target effects of a single gRNA are compared here, other 
studies have documented that dCas9-DNMT3a fusion proteins have large off-target 
effects irrespective of the gRNA used
153,154
.  
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HARDEN can also be used to make stably methylated cell lines that model epigenetic 
alterations seen in ALS/FTD patients with the C9orf72 repeat expansion
47,136,137
. Indeed, 
this study confirms for the first time that the endogenous C9orf72 promoter CpG island 
directly regulates expression of this gene and that DNA methylation of this region leads 
to an increase in histone H3K9 trimethylation. Interestingly, the overall levels of 
methylation in clonal iPSCs are lower than in clonal HEK293Ts. This could be due to 
differences in active demethylation between the cell types or selective pressure against 
fully methylated C9orf72 in iPSCs. It is known that iPSCs require active demethylation 
via TET enzymes to maintain pluripotency
184
.  
We acknowledge that HARDEN may not the best targeted DNA methylation technique 
for some applications. Since HARDEN appears to be linked to HDR, methylation 
efficiency is dependent on HDR rates which can be low or absent in certain settings.  For 
instance, targeting post-mitotic cells or cell types that have a low frequency of HDR may 
limit the utility of this method. Furthermore, since stable methylation editing requires 
both a gRNA and repair template, multiplexing to target several genes at once would be 
labor intensive. A final limitation is that in order to prevent cutting of the repair template, 
a PAM mutation is required and thus scarless methylation editing without changing the 
DNA sequence is difficult. Nevertheless, the cellular models established here using 
HARDEN can be utilized to better understand the molecular consequences of C9orf72 
hypermethylation in the context of the repeat expansion.  
 
Figures 
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Figure 2.1: Editing DNA methylation of C9orf72 using single stranded DNA templates 
A) Diagram of C9orf72 gene structure. Red arrows indicate primers used for MSRE-
qPCR. The forward primer anneals outside of the repair template. Green line indicates 
HhaI site that is being tested for methylation in (B). B) MSRE-qPCR of a CpG site within 
the C9orf72 promoter in HEK293T cells transfected with CRISPR/cas9 plasmid and the 
indicated single stranded oligonucleotide repair templates. Cells were collected 2 days 
post transfection. n =3 experiments. One way ANOVA followed by Bonferroni pairwise 
comparisons. All groups with gRNA are significantly different than those without gRNA. 
****p < 0.0001, ***p < 0.001, **p < 0.01. C) Representative PCR + Digest with T7 
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endonuclease I from experiments shown in (B). Digest with T7 estimates the total amount 
of mismatched DNA (Indels and copying of the 2bp PAM mutation via HDR). D) 
Representative PCR + digest with SspI restriction enzyme from experiments shown in 
(B). SspI digest estimates the rate of HDR (copying of the 2bp PAM mutation creates 
SspI restriction enzyme site). n = 6 experiments. E) Quantification of T7 and SspI Digest 
assays. n =6 experiments. 2 way ANOVA shows significant interaction between sample 
group and digest assay (p = 0.0004). Bonferroni Post hoc tests were carried out between 
groups within each assay.  F) MSRE-qPCR timecourse of HEK293T cells transfected 
with Cas9+gRNA and no repair template. n =3 experiments. G) MSRE-qPCR timecourse 
of HEK293T cells transfected with Cas9 and ssoligo repair templates. n =3 experiments. 
2 way ANOVA shows significant interaction between time post transfection and template 
(p = 0.0010). Comparisons are made to Cas9 without gRNA transfected group. ****p < 
0.0001, **p < 0.01, *p < 0.05. H) MSRE-qPCR of HEK293T cells transfected with 
Cas9+gRNA and either a fully unmethylated template, a fully methylated template or a 
template with a single methyl-CpG on the HhaI site. Cells were collected days post 
transfection. n =6 experiments. One way ANOVA followed by Bonferroni pairwise 
comparisons. **p < 0.01, *p < 0.05. 
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Figure 2.2: Editing DNA methylation with double-stranded repair templates. A) Diagram 
of double stranded DNA repair templates (either fully methylated or fully unmethylated 
at CpG sites) homologous to the C9orf72 promoter. Red box indicates a 2 bp substitution 
that generates a restriction enzyme site and mutates the PAM sequence. B) MSRE-qPCR 
assay to measure DNA methylation using a long amplicon that anneals outside the repair 
templates. HEK293T cells were transfected with CRISPR/Cas9+gRNA and the indicated 
templates. Cells were puromycin selected for 2 days and collected at day 4 post 
transfection. n =3 experiments; 2 way ANOVA shows significant interaction between 
template length and template methylation status (p = 0.0071). Bonferroni post hoc test 
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between unmeth and meth template groups ****p < 0.0001, *** p < 0.001. C) 
Comparison of methylation efficiency between HARDEN method and dCas9-DNMT3a 
fusion protein construct. HEK293T cells were transfected with indicated plasmids and 
methylation was measured 2 days post transfection using long amplicon MSRE-qPCR.  n 
=3 experiments. One way ANOVA (p < 0.0001) followed by Bonferroni comparison of 
indicated groups. ****p < 0.0001, **p < 0.01, *p < 0.05. D) Timecourse of methylation 
measured via long amplicon MSRE-qPCR using 1.4kb dsDNA repair templates. n =3 
experiments. 2 Way ANOVA (Group p < 0.0001; day post transfection p = 0.0343) 
followed by Bonferroni comparison between unmethylated template and methylated 
template groups. ** p < 0.01. E) Diagram of C9orf72 promoter region indicating the 
position of the repair template used to generate stably methylated HEK293T clones. Red 
box indicates a 2 bp substitution that generates a restriction enzyme site and mutates the 
PAM sequence. F) PCR and digest of HEK293T clonal lines that were repaired using the 
1.4kb dsDNA repair templates. Cells were collected ~5 weeks post transfection. G) 
MSRE-qPCR of clonal cell lines that were homozygous for editing with either the 
unmethylated (n =2) or methylated 1.4kb repair template (n =3). Cells were collected ~5 
weeks post transfection. Two tailed t-test; p = 0.0020. H)  Bisulfite amplicon sequencing 
of homozygous clonal cell lines edited with the unmethylated or methylated 1.4kb repair 
templates. Cells were collected ~5 weeks post transfection. Each row is an individual 
DNA molecule and columns are individual CpG dinucleotides. Grey boxes indicate 
unmethylated CpGs, black boxes indicate methylated CpGs and white boxes are 
undetermined due to poor conversion or poor sequencing quality.  
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Figure 2.3: DNA methylation is associated with Homology Directed Repair. A) Diagram 
showing the targeted region of C9orf72. Purple arrows indicate primers that amplify wild 
type DNA, whereas the red arrow indicates the primer that specifically amplifies a 12bp 
mutation that was included in the repair template. B) Bisulfite PCR using the primers 
depicted in (A). Representative gel from two biological replicates. C) Bisulfite amplicon 
sequencing from two biological replicates (Unmeth: n= 27 amplicons, Meth: n =31 
amplicons). Each row is an individual cloned and sequenced DNA molecule and columns 
are individual CpG dinucleotides. Grey boxes indicate unmethylated CpGs, black boxes 
indicate methylated CpGs and white boxes are undetermined due to poor conversion or 
poor sequencing quality. D) Quantification of percent methylation at each CpG site 
sequenced in (C). n =2 biological replicates and 22 CpG sites. E) Quantification of the 
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number of amplicons with less than or greater than 20% methylation. Data are from 2 
biological replicates. Fisher’s Exact Test, p < 0.0001. 
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Figure 2.4: Genome-wide methylation analysis of HARDEN and Cas9-DNMT3a based 
methods. A) Methylation values from HEK293T cells transfected with Cas9+gRNA to 
C9orf72 and a methylated repair template vs those without gRNA. Methylation was 
measured on an Illumina Epic Methylation Array with ~800,000 probes. Cells were 
puromycin selected and collected at day 4 post transfection. n =3 biological replicates; 
Colored dots indicate differentially methylated probes calculated using the Benjamini–
Hochberg procedure. Black = not significant (adjusted p > 0.05); Yellow = adjusted p < 
0.05; Red = adjusted p < 0.01. B) Methylation values from HEK293T cells transfected 
with either dCas9-DNMT3a or catalytically dead dCas9-DNMT3-ANV along with 
gRNA to C9orf72. Cells were puromycin selected and collected at day 4 post 
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transfection. n =3 biological replicates. Methylation was measured on an Illumina Epic 
Methylation Array with ~800,000 probes. Colored dots indicate differentially methylated 
probes calculated using the Benjamini–Hochberg procedure. Black = not significant 
(adjusted p > 0.05); Yellow = adjusted p < 0.05; Red = adjusted p < 0.01. C) Raw 
methylation values vs the density of probes genome-wide for non-transfected cells (n =2), 
Cas9+gRNA and methylated template (n =3) or Cas9 without gRNA and methylated 
template (n =3). Methylation was measured on an Illumina Epic Methylation Array with 
~800,000 probes. D) Raw methylation values vs the density of probes genome-wide for 
non-transfected cells (n =2), dCas9-DNMT3a+gRNA to C9orf72 (N=3) or catalytically 
dead dCas9-DNMT3-ANV+gRNA to C9orf72 (n =3). Methylation was measured on an 
Illumina Epic Methylation Array with ~800,000 probes.  
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Figure 2.5: Editing of DNA methylation in ALS patient derived iPSCs. A) PCR and 
digest of clonal ALS patient derived iPSCs that were repaired using 1.4kb double 
stranded dsDNA repair templates. B) MSRE-qPCR to measure DNA methylation of 
clonal iPSCs that were homozygous for editing with the repair template. Cells were 
puromycin selected for 2 days, subcloned at day 7 and collected at ~6 weeks post 
transfection.  n =2 measurements per cell line and 3-4 cell lines per group. C) Correlation 
between H3K9 trimethylation levels measured by ChIP-qPCR (n =2 experiments and 3 
cell lines per group) and DNA methylation measured by MSRE-qPCR. Linear regression, 
R
2 
= 0.9242; p = 0.0022. D)  Bisulfite amplicon sequencing from unmethylated or 
methylated clonal iPSCs (n= 3 cell lines per group). Each row is an individual cloned and 
sequenced DNA molecule and columns are individual CpG dinucleotides. Grey boxes 
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indicate unmethylated CpGs, black boxes indicate methylated CpGs and white boxes are 
undetermined due to poor conversion or poor sequencing quality. E)  Diagram of 
C9orf72 gene structure. Black triangle indicates the Cas9 cut site, colored arrows indicate 
transcription start site and black arrow indicates the protein coding start site. F) RT-qPCR 
of all C9orf72 variants in methylated or unmethylated clonal iPSCs. n =3 cell lines per 
group. Two-tailed t-test, p = 0.0021 G) RT-qPCR of C9orf72 variant 2 in methylated or 
unmethylated clonal iPSCs. n = 3 cell lines per group.  Two-tailed t-test, p = 0.0056. H) 
RT-qPCR of C9orf72 variant 3 in methylated or unmethylated clonal iPSCs. n =3 cell 
lines per group. Two-tailed T-test, p = 0.0048. 
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Supplemental Figures and Tables 
 
 
Supplemental Figure 2.1: Comparison of HDR efficiency in different length templates. 
Quantification of PCR + SspI Digest in HEK293T cells transfected with the indicated 
templates. Cells were puromycin selected for 2 days and collected at day 4 post 
transfection. n = 3 experiments. 2 way ANOVA shows template size has significant 
effect (p < 0.0001) whereas methylation status does not (p = 0.6110). Bonferroni post hoc 
tests were carried out between unmeth and meth groups at each template length. 
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Supplementary Figure 2.2: Comparison of ssDNA vs dsDNA templates. MSRE-qPCR 
of HEK293T cells transfected with either 190bp ssOligo or 190bp dsDNA methylated 
templates and the CRISPR/cas9 components. Cells were puromycin selected for 2 days 
and collected at day 4 post transfection. n = 3 experiments. One Way ANOVA (p = 
0.0126) followed by Bonferroni test. 
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Supplementary Figure 2.3: MSRE-qPCR of HEK293T clonal lines repaired with either 
an unmethylated or methylated repair template. Cells were analyzed for HDR and 
methylation ~5 weeks post transfection. Shown here are clones that had at least 25% 
HDR (measured via SspI digest). n = 16 unmeth clones, 13 meth clones. Two-Tailed T-
Test, p = 0.0004.  
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Supplementary Figure 2.4: Effect of DNMT knockdown on targeted methylation of 
C9orf72. siRNA was transfected 24 hours prior to transfection of CRISPR components 
and 1.4kb methylated template into HEK293T cells. Cells were collected 4 days post 
transfection. Methylation was measured via long amplicon MSRE-qPCR and normalized 
to scrambled control. n = 3 experiments; 1 way ANOVA followed by Bonferroni post 
hoc tests. *** p < 0.001; **** p < 0.0001. 
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Supplementary Figure 2.5: Repeat Primed PCR of iPSCs derived from ALS patient 
with C9orf72 repeat expansion. Capillary electrophoresis traces from fluorescently 
labeled repeat primed PCR on unedited or edited clonal iPSC lines repaired with either 
the 1.4kb unmethylated dsDNA template or methylated dsDNA template.  
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Supplementary Figure 2.6: H3K9me3 chromatin immunoprecipitation followed by 
qPCR of unmethylated and methylated clonal iPSCs. Off-target positive control is the 
PAPC1 gene body, whereas the negative control is the PAPC1 promoter region. n = 3 cell 
lines per group and 2 technical replicates. One way ANOVA (p = 0.0001) followed by 
Bonferroni post hoc tests between indicated groups. **p < 0.01. 
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Table 2.S1: Primers and gRNA sequences 
Forward Primer Sequence (5’-3’) Reverse Primer Sequence (5’-3’) Assay 
CAGTGTGAAAATCATGCTTGAGAGA TTTGTGCTTGGTAGGCAGTG 
DNA methylation 
analysis q-PCR; 
ChIP-qPCR 
TGCTCTTTGAGAAAATTCATTGG TTTGTGCTTGGTAGGCAGTG 
DNA methylation 
analysis q-PCR 
(long templates) 
TGGCACTATTAAGGATCTGAGGAG GGAGAGAGGGTGGGAAAAAC 
HDR analysis 
PCR (long 
templates) 
TACCAGGGTTTGCAGTGGAG GGAGAGAGGGTGGGAAAAAC 
T7/HDR analysis 
(oligo templates) 
GGAGTTGTTTTTTATTAGGGTTTGTAGT TAAACCCACACCTACTCTTACTAAA 
Bisulfite Cloning 
PCR 
AGTTTTTTTTATTAAGGTTYGTATA TTTCTTCTAATTAATCTTTATCAA 
Bisulfite Cloning 
Primer Insert - WT 
TTTAGTAGTTTTTGAATAATATTGG TTTCTTCTAATTAATCTTTATCAA 
Bisulfite Cloning 
Primer Insert - 
Mutant 
CCCACTTCATAGAGTGTGTGTTG TTCCATTCTCTCTGTGCCTTC 
Total C9orf72 
mRNA (all 
variants) 
CGGTGGCGAGTGGATATCTC TGGGCAAAGAGTCGACATCA 
C9orf72 variant 2 
mRNA 
GCAAGAGCAGGTGTGGGTTT TGGGCAAAGAGTCGACATCA 
C9orf72 variant 3 
mRNA 
6FAM-AGTCGCTAGAGGCGAAAGC TACGCATCCCAGTTTGAGACG 
C9orf72 Repeat 
Expansion 
Detection 
TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCCGGGG   
C9orf72 Repeat 
Expansion 
Detection 
CACCGTAGCGTGTGCGAACCTTAAT AAACATTAAGGTTCGCACACGCTAC 
CRISPR gRNA 
sequences (oligos 
for cloning) 
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Table 2.S2: Repair template sequences with PAM mutation highlighted 
Name Sequence Length (bp) 
Non-
homologous 
template 
CAGAAGAAGAAGGGCTCCCATCACATCAACCGGTGGCGCATTGCCACGAAGCAGGCCAATGGGGAGGACATCGATGTCACCTC
CAATGACAAGTTGCT 
AGCGGTGGGCAACCACAAACCCACGAGGGCAGAGTGCTGCTTGCTGCTGGCCAGGCCCCTGCGTGGGCCCAAGCTGGACTCT
GGCCACTCCCT 
191 
190bp ssOligo 
template  
CTAGCGAAATGGGGCGGGGCAACTTGTCCTGTTCTTTTATCTTAAGACCCGCTCTGGAGGAGCGTTGGCGCAATAGCGTGTGCG
AAC 
CTTAATATTGGAGGCTGCTGGATCTGGAGAAAGTGAAGACGATTTCGTGGTTTTGAATGGTTTTGTTTGTGCTTGGTAGGCAGTG
GGCGCTCAACACATAATT 
190 
600bp dsDNA 
template  
AGGCACCGCAACCGCAGCCCCGCCCCGGCCCCTAGCGCGCGACTCCTGAGTTCCAGAGCTTGCTACAGGCTGCGGTTGTTTCCCTCCTTGTTTTCTTCTGGTTAATCTTTATCAGGTCTTTTCTTGTTCACCCTCAGCGAGTACTGTGAGAGCAAGTAGTGGGGAGAGAGGGTGGGAAAAACAAAAACACACACC
TCCTA 
AACCCACACCTGCTCTTGCTAGACCCCGCCCCCAAAAGAGAAGCAACCGGGCAGCAGGGACGGCTGACACACCAAGCGTCATCTTTTACGTGGGCGGAACTTGTCGCTGTTTGACGCACCTCTCTTTCCTAGCGGGACACCGTAGGTTACGTCTGTCTGTTTTCTATGTGCGATGACGTTTTCTCACGAGGCTAGCGAAATGGGGCGGG 
GCAACTTGTCCTGTTCTTTTATCTTAAGACACGCTCTGGATGAGCGTTGGCGCAATAGCGTGTGCGAACCTTAATATTGGAGGCTGCTGGATCCGGAGAAAGTGAAGACGATTTCGTGGTTTTGAATGGTTTTGTTTGTGCTTGGTAGGCAGTGGGCGCTCAACAAATAATTGGTGGATGAAATTTTGTTTTTACC
GTAAGACACTGTTAAG 
621 
1.4kb dsDNA 
template 
CCCCGCCCCGGGCCCGCCCCCGGGCCCGCCCCGACCACGCCCCGGCCCCGGCCCCGGCCCCTAGCGCGCGACTCCTGAGTTCCAGAGCTTGCTACAGGCTGCGGTTGTTTCCCTCCTTGTTTTCTTCTGGTTAATCTTTATCAGGTCTTTTCTTGTTCACCCTCAGCGAGTACTGTGAGAGCAAGTAGTGGGG
AGAGAGGGTGGGAAAAACAAAAACACACACCT 
CCTAAACCCACACCTGCTCTTGCTAGACCCCGCCCCCAAAAGAGAAGCAACCGGGCAGCAGGGACGGCTGACACACCAAGCGTCATCTTTTACGTGGGCGGAACTTGTCGCTGTTTGACGCACCTCTCTTTCCTAGCGGGACACCGTAGGTTACGTCTGTCTGTTTTCTATGTGCGATGACGTTTTCTCACGAGGCTAGCGAAATGGGGC
GGGGCAACTTGTCCTGTTCTTTTATCTTAAGACCCG 
CTCTGGAGGAGCGTTGGCGCAATAGCGTGTGCGAACCTTAATATTGGAGGCTGCTGGATCTGGAGAAAGTGAAGACGATTTCGTGGTTTTGAATGGTTTTGTTTGTGCTTGGTAGGCAGTGGGCGCTCAACACATAATTGGTGGATGAAATTTTGTTTTTACCGTAAGACACTGTTAAGTGCATTCAAAACTCCAC
TGCAAACCCTGGTAGGGGACAGCTCCGGC 
ACTGCGGGCGGGAATCCCACGGTCCCCTGCAAAGTCATCGCAATTTTGCCTTTACATGTAAGAATTCTCTCAAGCATGATTTTCACACTGGGGAATGTCATTTTTGCTAGTTGCAATATGTGGATGAGTTGTTTTTTTTTAACTTTTGAAAAACGTACCATTCTGTTTGATGTGTAAAAAACACAAAGATTTTTGAAACCTTGCGTCTTTTGGTCTG
CAGGTGTATAGATTCCACTTACTACAGA 
TGAGTAGCATTTACACCACTCAGATGTGTAAAAAAACAAAGGTTTTTTAAACTGTGTGCCTTTTGATCTGCAAGTGTGAGATGGCACTTACTACAGTGAGTAGCATTTAATCTTTTTCATCACTAAAAATCACACAGAACGTTTTAATCATTCACCGAGGAAGAAAGGGAGGAATAAATACACAAAATGGCTCTCAACGTCTACACCTTCTGCAGA
AACAGACCCTTTTCCTACTGTTCTATG 
CTTTGTGAAAGTTGATCATACAAATTGGGTCATTCTTTTTATACCCAACTAAAATAGTGGGGGTAGGGGGTAGAAAAGCACTTAGGACAAATGACACTGCTCCCACAGTGTAATTCTCTCCAAGTCCAGCTGCTGCAACTGCCCGTTGTGACCTGAGACCAGTTTTATCTAATAGTTGCTAAAATGACCTGCTGCAGCTCTAATTTTATCTACCA
CCATCACTCACCAGTT 
1415 
PCR-insert 
template 
AACTGGTGAGTGATGGTGGTAGATAAAATTAGAGCTGCAGCAGGTCATTTTAGCAACTATTAGATAAAACTGGTCTCAGGTCACAACGGGCAGTTGCAGCAGCTGGACTTGGAGAGAATTACACTGTGGGAGCAGTGTCATTTGTCCTAAGTGCTTTTCTACCCCCTACCCCCACTATTTTAGTTGGGTATAAAAAGA
ATGACCCAATTTGTATGATCAACTTTCACAAA 
GCATAGAACAGTAGGAAAAGGGTCTGTTTCTGCAGAAGGTGTAGACGTTGAGAGCCATTTTGTGTATTTATTCCTCCCTTTCTTCCTCGGTGAATGATTAAAACGTTCTGTGTGATTTTTAGTGATGAAAAAGATTAAATGCTACTCACTGTAGTAAGTGCCATCTCACACTTGCAG 
ATCAAAAGGCACACAGTTTAAAAAACCTTTGTTTTTTTACACATCTGAGTGGTGTAAATGCTACTCATCTGTAGTAAGTGGAATCTATACACCTGCAGACCAAAAGACGCAAGGTTTCAAAAATCTTTGTGTTTTTTACACATCAAACAGAATGGTACGTTTTTCAAAAGTTAAAAAAAAACAACTCATCCACATATTGCAACTAGCAAAAATGACA
TTCCCCAGTGT 
GAAAATCATGCTTGAGAGAATTCTTACATGTAAAGGCAAAATTGCGATGACTTTGCAGGGGACCGTGGGATTCCCGCCCGCAGTGCCGGAGCTGTCCCCTACCAGGGTTTGCAGTGGAGTTTTGAATGCACTTAACAGTGTCTTACGGTAAAAACAAAATTTCATCCACCAATTATGTGTTGAGCGCCCACTGCCTACCAAGCACAA 
ACAAAACCATTCAAAACCACGAAATCGTCTTCACTTTCTCCAGATCCAGCAGCCTCCGAATAATATTGGCCTATTAAGGTTCGCACACGCTATTGCGCCAACGCTCCTCCAGAGCGGGTCTTAAGATAAAAGAACAGGACAAGTTGCCCCGCCCCATTTCGCTAGCCTCGTGAGAAAACGTCATCGCACATAGAA
AACAGACAGACGTAACCTAC 
GGTGTCCCGCTAGGAAAGAGAGGTGCGTCAAACAGCGACAAGTTCCGCCCACGTAAAAGATGACGCTTGGTGTGTCAGCCGTCCCTGCTGCCCGGTTGCTTCTCTTTTGGGGGCGGGGTCTAGCAAGAGCAGGTGTGGGTTTAGGAGGTGTGTGTTTTTGTTTTTCCCACCCTCTCTCCCCACTACTTGCTCTCACAGTA
CTC 
1248 
 
 
 
Data Availability 
Genome-wide DNA methylation array data is publically available at GEO (GSE134996).  
Acknowledgements 
We thank Madlyn Kates for technical assistance. 
Funding 
This study was supported by a grant from the NIH (R01 NS095793).   
Conflicts of Interest 
The authors declare no conflicting interests. 
63 
 
Chapter 3: C9orf72 intermediate repeats and corticobasal degeneration 
 
This chapter is adapted from a published manuscript:  
Reprinted by permission from Springer Nature Customer Service Centre GmbH (License number: 
4644790595463). © 2019 Springer Nature.  
Citation: 
Cali CP, Patino M, Tai YK, et al. C9orf72 intermediate repeats are associated with corticobasal 
degeneration, increased C9orf72 expression and disruption of autophagy. Acta Neuropathol. July 
2019:1-17. doi:10.1007/s00401-019-02045-5. 
Corresponding Author:  
Edward B. Lee 
613A Stellar Chance Laboratories 
422 Curie Blvd 
Philadelphia, PA 19104 
edward.lee@pennmedicine.upenn.edu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
64 
 
 
 
Abstract 
 
Microsatellite repeat expansion disease loci can exhibit pleiotropic clinical and 
biological effects depending on repeat length. Large expansions in C9orf72 (100s-1000s 
of units) are the most common genetic cause of amyotrophic lateral sclerosis (ALS) and 
frontotemporal degeneration (FTD). However, whether intermediate expansions also 
contribute to neurodegenerative disease is not well understood. Several studies have 
identified intermediate repeats in Parkinson’s disease patients, but the association was not 
found in autopsy confirmed cases. We hypothesized that intermediate C9orf72 repeats are 
a genetic risk factor for corticobasal degeneration (CBD), a neurodegenerative disease 
that can be clinically similar to Parkinson’s but has distinct tau protein pathology.  
Indeed, intermediate C9orf72 repeats were significantly enriched in autopsy-proven CBD 
(n=354 cases, odds ratio=3.59, p-value=0.00024).  While large C9orf72 repeat 
expansions are known to decrease C9orf72 expression, intermediate C9orf72 repeats 
result in increased C9orf72 expression in human brain tissue and CRISPR/cas9 knockin 
iPSC derived neural progenitor cells. In contrast to cases of FTD/ALS with large C9orf72 
expansions, CBD with intermediate C9orf72 repeats was not associated with pathologic 
RNA foci or dipeptide repeat protein aggregates.  Knock-in cells with intermediate 
repeats exhibit numerous changes in gene expression pathways relating to vesicle 
trafficking and autophagy. Additionally, overexpression of C9orf72 without the repeat 
expansion leads to defects in autophagy under nutrient starvation conditions. These 
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results raise the possibility that therapeutic strategies to reduce C9orf72 expression may 
be beneficial for the treatment of CBD. 
Introduction 
 
Large hexanucleotide repeat expansions (G4C2) in C9orf72 are the most common 
genetic cause of the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and 
frontotemporal degeneration (FTD)
43,44,116
. ALS/FTD is characterized 
neuropathologically by the presence of TDP-43 inclusions which are tightly linked to 
neurodegeneration
34
.  While the pathophysiologic mechanisms that lead to TDP-43 
aggregation and neurodegeneration in the setting of large C9orf72 repeat expansions are 
still unclear, both a loss of normal C9orf72 function and a toxic gain of function 
attributed to repetitive RNA and protein aggregates have been proposed
43,44,81,88,115
. At 
the protein level, C9orf72 regulates several vesicle trafficking pathways 
56,67,70
 and is 
necessary for proper myeloid cell function in mice, but knockout of the protein does not 
cause neurodegeneration
58,59
. On the other hand, the presence of the repeat expansion is 
sufficient to induce neurodegeneration in several mouse models
84,109
. There is also 
uncertainty in the repeat size threshold necessary to cause disease. Repeat expansions that 
cause ALS/FTD are typically hundreds to thousands of units long and can differ 
substantially between tissues
45,185
, making it difficult to accurately determine the 
pathogenic repeat size threshold. There have been reports of pathogenic repeats as small 
as 55-100 units in patient blood
117,118
.  In contrast, non-diseased individuals typically 
harbor repeats of 2-8 units
186
. Several studies have explored whether intermediate 
C9orf72 expansions (e.g. those larger than controls but not large enough to cause 
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ALS/FTD) are associated with risk for other neurodegenerative diseases, and these have 
often yielded conflicting results
119,124,125,186–191
.  For instance, a significant association 
between intermediate expansion carriers and Parkinson’s Disease (PD) was reported in 
clinically diagnosed PD
125
 and confirmed in a large meta-analysis
123
, but these 
associations were not found in an autopsy confirmed PD cohort
126
.  Other studies with 
very small numbers of cases have also suggested that intermediate C9orf72 repeats are 
associated with atypical Parkinsonian syndromes
192,193
.  Thus, there is some evidence that 
intermediate expansions in C9orf72 may confer risk for neurodegenerative diseases other 
than ALS/FTD, but more exploration is needed to better understand the molecular 
pathways and exact neurodegenerative diseases that are affected. 
Here, we sought to determine whether intermediate expansions in C9orf72 are a 
risk factor for corticobasal degeneration (CBD), a rare neurodegenerative disease that 
shares some similar clinical features with PD such as limb rigidity, bradykinesia, tremor 
and apraxia
194
. Patients that present with these neurologic features are often diagnosed 
with corticobasal syndrome (CBS) because these symptoms can also be caused by several 
other neurodegenerative diseases; definitive diagnosis of CBD requires neuropathology 
autopsy examination
195
.  CBD is characterized by hyper-phosphorylated tau aggregates in 
neurons and astrocytes that are morphologically distinct from those found in Alzheimer’s 
disease and other tauopathies
196
. Only ~25-50% of patients diagnosed with CBS are 
confirmed as CBD at autopsy
197–199
,  making clinically defined cohorts difficult to use for 
genetic studies of CBD due to underlying neuropathological heterogeneity.  In this study, 
we determine whether C9orf72 intermediate expansions may be a risk factor for CBD by 
measuring repeat size in the largest cohort of autopsy confirmed cases ever tested. In 
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addition, we use post mortem CBD brain tissue to confirm the genetic findings, use 
CRISPR/cas9 to modify the repeat number in human iPS cells at the endogenous locus, 
and determine the effects of C9orf72 expression on autophagy. In doing so, we identify a 
novel mechanism for how intermediate repeat expansions may affect CBD pathogenesis 
that is distinct from large expansions that cause ALS/FTD. 
 
Materials and Methods 
 
Case Samples 
Genomic DNA for repeat expansion size screening was obtained from 354 autopsy 
confirmed CBD cases from 17 institutions.  Institutions contributing the vast majority of 
cases included Mayo Clinc, University College London and the University of 
Pennsylvania. CBD patient cerebellum tissue for RNA expression studies was obtained 
from the Center for Neurodegenerative Disease Research brain bank at the University of 
Pennsylvania and from the Mayo Clinic brain bank. Brain autopsy material is not 
considered human subjects research.  However, legal consent for autopsy was obtained in 
all instances. As a control cohort, we utilized a previously published global cohort of 
healthy controls for which C9orf72 repeat sizing was available
123
. 
 
Assessment of Repeat Expansion Size and SNP Genotyping 
The CBD cohort was screened for intermediate C9orf72 repeat expansions using 
fluorescent labeled touchdown PCR followed by fragment-length analysis on an ABI 
3130xl Genetic Analyzer (Applied Biosystems, Foster City, CA). PCR used 50ng 
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genomic DNA in a final volume of 20ul containing 0.5U of Amplitaq Gold (Applied 
Biosystems) and a final concentration of 1x Amplitaq Buffer I, 5uM reverse primer, 5uM 
6FAM-fluorescent labeled forward primer, 1M Betaine, 5% DMSO, 0.25mM 7-deaza-
dGTP, and 0.25mM of each dNTP. For detection of full expansions using repeat-primed 
PCR, the Roche FastStart (Roche, Basel, Switzerland) polymerase system was used to 
amplify 1ug of genomic DNA in a reaction with 0.9 mM MgCl2, 200nM dNTP mix, 
180nM 7-deaza-dGTP, 1.4uM flanking primers, 0.175uM  repeat primer, 7% DMSO, 
.93M Betaine and 0.125 U polymerase. For both intermediate and full expansion 
detection, a touchdown PCR cycling program was used where the annealing temperature 
was gradually lowered from 70°C to 56°C in 2°C increments with a 3-minute elongation 
time at 72°C for each cycle. SNP genotyping was carried out using Taqman probes as 
previously described
43
.  All primer sequences are listed in Supplemental Table 3.1. 
 
Detection of RNA foci  
RNA foci detection was performed on paraffin embedded cerebellum sections as follows: 
Slides were deparaffinized with Xylene, followed by Xylene/Ethanol (1:1) and then 
rehydrated with an ethanol series (100%, 90%, 80%,70% for 3 mins each). Slides were 
incubated for 5 minutes in water, then digested with proteinase K (20ug/mL) for 10 
minutes at 37 degrees in a buffer containing 10mM Tris-HCL pH 8 and 0.5% SDS in 
DEPC-treated water. Slides were then washed twice with water then dehydrated with 
increasing ethanol series and allowed to air dry. Slides were then prehybridized for 1 
hour at 66 degrees in hybridization buffer containing 50% Foramide, 2X SSC, 50mM 
NaHPO4 , and 10% Dextran sulfate in DEPC-treated water. Slides were hybridized with 
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40nM probe (LNA 5TYE563C4G2; Exiqon (Denmark) # 300500, batch # 621440) at 66 
degrees overnight. Slides were then washed once with 2X SSC + 0.1% Tween for 5 mins 
at room temperature, then 3 times with 0.1X SSC for 10 minutes at 65 degrees. Slides 
were then rinsed with water, stained with DAPI and mounted with coverslips using 
Prolong glass antifade mountant (Invitrogen, Carlsbad, CA).  Cases for RNA foci 
detection included 12 non-expanded CBD, 9 intermediate CBD, 4 non-expanded control 
cases (negative control) and 5 full expansion FTD/ALS cases (positive control).  
 
Detection of Dipeptide Repeat proteins and Measurement of DNA methylation 
Paraffin embedded cerebellum sections were deparaffinized and stained with antibodies 
against p62, GA (1:7500), GP (1:7500) or GR (1:100) as previously described
200
. 116 
non-expanded CBD, 9 intermediate CBD, 4 non-expanded control cases (negative 
control) and 5 full expansion FTD/ALS cases (positive control) were stained. For 
measurement of DNA methylation in CBD patient genomic DNA, 100ng DNA was 
digested using the restriction enzymes HhaI and HaeIII (New England Biolabs, Ipswich, 
MA) followed by qPCR as previously described
137
. 
 
RNA Expression Analysis from Postmortem Brain and repeat edited NPCs 
RNA was extracted from approximately 100mg of cerebellum tissue using Trizol reagent 
(Life Technologies, Carlsbad, CA). RNA integrity was tested on an Agilent 2100 
bioanalyzer using the RNA Nanochip 6000 kit (Agilent, Santa Clara, CA). Only RNA 
samples with RIN values > 6 were included in this study. For repeat edited NPCs, cells 
were pelleted at day 12 post induction and RNA was extracted using the RNeasy Kit 
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(Qiagen). cDNA was prepared using random hexamers and Superscript III (Invitrogen) 
according to manufacturer’s protocol. RT-qPCR was performed using SYBR Green 
reagents (Roche) on a StepOne Plus Real-Time PCR Machine (Life Technologies). RNA 
levels were normalized to the geometric mean of two housekeeping genes (ACTB, GPS1) 
using the ∆∆Ct method. All primer sequences are listed in Supplemental Table 3.1. 
 
CRISPR Editing of Repeat Size 
CRISPR gRNAs were designed using the MIT CRISPR design tool 
(http://crispr.mit.edu/) and cloned into the Cas9-GFP PX458 vector (Addgene, 
Cambridge, MA) as previously described
201
. Repair templates were generated via PCR 
cloning using genomic DNA from intermediate repeat carriers. PCR was carried out 
using the FastStart Polymerase (Roche) with additives for GC rich templates (360nM 7-
deaza-dGTP, 7% DMSO, 930mM Betaine). PCR products containing 2 or 28 repeats 
were cloned into pGEM Easy-T vector (Promega, Madison, WI) and verified by 
sequencing. A 2 bp substitution was made at the PAM site in the repair template using 
QuickChange site directed mutagenesis (Aligent) in order to prevent Cas9 cutting of the 
repair template and to incorporate a restriction enzyme site (See Supplemental Figure 
3.3). PX458 and repair template vectors were co-transfected into WT iPSCs
202
 using 
Viafect reagent (Promega). On day 2 post transfection, GFP+ cells were sorted via FACS 
(BD FACS Aria II) to 96 well plates for clonal isolation. DNA was extracted from 24 
well plates of confluent clones using 0.2% SDS lysis buffer followed by phenol-
chloroform extraction. DNA from clones was PCR amplified and screened for homology 
directed repair by restriction enzyme digest. Repeat size was measured as outlined above 
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on positive clones, and all CRISPR edited cell lines were Sanger sequenced via PCR 
cloning (10 clones/cell line).  
 
Differentiation of iPSCs to Neural Progenitor Cells 
IPSCs were differentiated via dual SMAD inhibition as previously described
203
. Single 
cells were plated at high density (2x10
5
/cm
2
) in mTeSR1 (StemCell Technologies, 
Vancouver, Canada) + 10uM ROCK inhibitor Y27632 (ATCC) on Matrigel (Corning, 
Corning, NY) coated 6 well plates. The following day, media was changed to neural 
induction media (see Shi et al.
203
 for complete formulation) containing 10uM SB431542 
(Tocris, Bristol, United Kingdom) and 1uM dorsomorphin (Sigma, St. Louis, MO). 
Neural induction media was changed each day. At day 6, cells were split 1:2 into neural 
induction media + ROCK inhibitor and media changes were continued until day 12. Day 
12 NPCs were characterized for expression of NPC markers by immunofluorescence and 
RT-qPCR.  For western blot analysis, NPCs were passaged again at day 12 and collected 
at day 16 post induction.  
 
Western Blots and Antibodies  
For detection of C9orf72, day 16 NPCs were pelleted, lysed (50mM Tris-HCl, 750mM 
NaCl, 5mM EDTA, 2% SDS) and sonicated using a probe sonicator (Sonics Vibra-cell), 
then spun at 21,000 g for 30 mins. BCA analysis (Pierce, Thermo Fisher) was performed 
on cleared lysate to quantify protein expression. 50ug of protein was run on an 8% Tris-
Glycine gel, transferred using the Transblot Turbo system (Biorad, Hercules, CA) to a 
nitrocellulose membrane and blocked for 1 hour at room temperature with Odyssey Licor 
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Blocking buffer (Licor, Lincoln, NE). Membranes were blotted with the following 
antibodies overnight at 4 degrees: anti-C9orf72 1:1000 (Millipore, Burlington, MA, 
ABN1645), anti-GAPDH  1:1000 (Cell signaling Technology, Danvers, MA  2118S). IR 
dye secondary antibodies (Licor) were used to detect protein on a Licor Odyssey. Protein 
was quantified using Image Studio software (Licor). 
For C9orf72 expression and autophagy experiments, cell  lysates  were  prepared  
in  ice-cold  radio  immunoprecipitation  assay  (RIPA)  buffer containing  150  mM  
NaCl,  1%  TritonX-100,  0.5%  sodium  deoxycholate,  0.1% SDS  and  50 mM  Tris  
(pH8.0)  supplemented  with  protease  and  phosphatase inhibitors  (PhosphoSTOP, 
Roche).  Cells were  lysed  for  20  min  and  centrifuged  for  10  min  at  13,500 rpm.  
Protein concentration of the  soluble  fractions  were  determined  using  BCA  reagent  
(Thermo  Fisher Scientific). 20-70ug  of total protein was  resolved  using  10%  or  12%  
denaturing polyacrylamide gel electrophoresis and transferred to PVDF membrane 
(Immobilon-P, PVDF). Proteins on PVDF membranes were blocked using 5% low-fat 
milk in TBST containing 0.1% Tween-20 and incubated with primary antibody in 
SuperBlock (TBS, Thermo Fisher Scientific) overnight at 4°C. The primary antibodies 
used were: LC3 (ProteinTech, 14600-1-AP, 1:1000), and GAPDH (ProteinTech, 60004-
1-Ig, 1:5000). The membranes were washed in TBST. Anti-rabbit  or  anti-mouse  horse-
radish  peroxidase  (HRP)  conjugated  secondary  antibodies (1:3000, Thermo Fisher 
Scientific) in 5% milk in TBST were incubated with the membranes for 1  hour  at room  
temperature.  The  membranes  were  incubated  with  WestPico  or  WestFemto 
chemiluminescent substrate (Thermo Fisher Scientific) and exposed to Amersham 
Hyperfilm ECL films (GE Healthcare Life Sciences). The films were developed using 
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Konica Minolta film developer. Protein band intensity was quantified using LI-COR 
Image Studio Lite. 
 
RNA sequencing in knockin intermediate repeat cells 
50 base pair paired end RNA sequencing was carried out on day 12 post induction 
isogenic NPC lines (See Supplemental Table 3.2) with 3 biological replicates per group 
and 2 technical replicates per cell line. Libraries were prepared using the TrueSeq 
Stranded mRNA and Ribo-zero rRNA removal kits (illumina, San Diego, CA). 
Sequencing was carried out on a Hiseq 2500 (illumina) and at least 100 million reads 
were generated per biological replicate. Adapter sequences were removed using 
Cutadapt
204
. Reads were aligned to the genome (GRCh38) using STAR (v2.6) 
205
 with the 
default mapping parameters and the read counts per gene were counted using the 
quantMode function and genecode v29 annotation. Differentially expressed genes 
between the short repeat group and intermediate repeat group were called using the 
DEseq2 program (v1.22)
206
 with default parameters. Over enrichment analysis of 
biological pathways was carried out using WebGestalt (2019) on genes that were either 
upregulated or downregulated (adjusted p-value < 0.05) in the intermediate repeat group. 
For comparison of genes dysregulated in full expansion carriers, differentially expressed 
gene lists  (adjusted p < 0.05 and >2 fold change) from two studies
81,83
 that compared 
gene expression in iPSC derived neurons with full expansions vs. low repeat controls 
were compared against the differentially expressed genes in this study (intermediate 
repeat vs low repeat).  
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Generation of stable C9orf72 expressing cell lines, transfection and drug treatments 
The generation of an inducible single-copy C9orf72 transgene using Flp-In TRex-HeLa 
cells was  as  described previously
207
. All  cell  lines  used  in  this  study  were  
maintained  in DMEM (GE  Healthcare  HyClone,  SH30243.01) with  10%  FBS  (GE  
Healthcare  HyClone, SV30160.03)  and  1%  Pen-Strep  (Thermo  Fisher  Scientific,  
15070063)  at  37°C  and  5% CO2.  Tetracycline (Sigma-Aldrich, T7660) was added 
(100 ug/ml)  for  18  h  to induce the expression of C9orf72 transgene. Parental HeLa 
cells treated with tetracycline were used as controls in the experiments shown in Figure 
3.6b and 3.7b. All plasmid transfections in cell lines were performed using Lipofectamine 
2000  (Thermo  Fisher  Scientific,  11668019)  or  TurboFect  (Thermo  Fisher Scientific, 
R0531) as per the manufacturer’s instruction. For autophagy experiments, Chloroquine  
(CQ, Sigma-Aldrich)  was  dissolved  in  water  (20  mM)  and  used  at 40μM in the 
media.  Autophagy induction using Earle’s Balanced Salt Solution (EBSS, Gibco) was 
incubated on cells following two successive PBS rinses. Incubation time for each 
condition is stated in the respective figure legends.  
Results 
 
Screening of CBD patient DNA for C9orf72 expansions 
To test the hypothesis that intermediate size expansions in C9orf72 are a risk factor for 
CBD, genomic DNA from 354 autopsy confirmed CBD cases was screened using a PCR-
based sizing assay (Figure 3.1a). We compared CBD patients to controls from a 
previously published global meta-analysis of C9orf72 repeat size 
123
. We found that 
1.84% of alleles from CBD cases (corresponding to 3.7%, or 13 cases) harbored 
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intermediate length repeat expansions compared to 0.52% of controls (Figure 3.1b-c, OR 
= 3.59, p = 0.00024).  This analysis was based on a minimum size cutoff of 17 which was 
determined a priori and based on prior independent studies
123,208
. The increase in C9orf72 
intermediate repeat allele frequency was not due to an increase in the frequency of the 
C9orf72 repeat expansion haplotype between CBD patients verses non-diseased controls 
or general global populations (Supplemental Table 3.3), and we did not detect any 
expansions larger than 29 repeats (Supplemental Table 3.4). We conducted a post-hoc 
analysis on our CBD cohort for each repeat length cut off below 18 repeats which 
revealed that repeats as low as 10 units were associated with CBD (p = 0.026, OR = 
1.36), where 61 out of 354 CBD cases had C9orf72 repeat alleles that were at least 10 
units.  This included 5 cases which had two alleles at 10 or greater.  Although this post-
hoc analysis is considered exploratory
209
, there appeared to be a somewhat graded 
increase in CBD risk with increasing repeat size (Figure 3.1d, Supplemental Table 3.5). 
Overall these results indicate that intermediate expansions in C9orf72 may be a genetic 
risk factor for CBD, and the risk may be additive with higher repeat sizes conferring 
increased CBD risk. 
 
C9orf72 expression from intermediate expansion carriers 
 Next, we determined how intermediate repeat expansions affect expression of the 
C9orf72 gene. Previous studies have shown that large expansions in C9orf72, which 
cause ALS/FTD, reduces mRNA from the expanded allele
43,54,210
. This reduction in 
expression is often associated with hypermethylation of the C9orf72 promoter 
region
47,136,137,140
. To test whether intermediate expansions alter C9orf72 DNA 
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methylation and mRNA levels, we analyzed post mortem cerebellum samples from a 
subset of 47 CBD cases for which frozen tissue was readily available. We measured 
repeat expansion size, DNA methylation and C9orf72 mRNA levels of the two major 
isoforms
62
 (Figure 3.2a, V2 and V3 isoforms). In this subgroup analysis, we again 
observed high frequencies of intermediate repeat expansions between 17 and 29 units 
(Supplemental Figure 3.1). Intermediate size expansions did not correlate with 
hypermethylation of the promoter region, as is observed in full expansion cases 
(Supplemental Figure 3.2). Surprisingly, total C9orf72 mRNA levels were positively 
correlated with total C9orf72 repeat size (Figure 3.2b left, R
2 
= 0.276, p = 0.0034).This 
positive correlation was not observed for the major isoform, V2, which has a 
transcription start site downstream from the repeat expansion (Figure 3.2c left, R
2
 = 
0.00496, p = 0.717). In contrast, V3 has a transcription start site upstream from the repeat 
expansion and shows a robust positive correlation between repeat expansion size and 
mRNA levels (Figure 3.2d left, R
2
 = 0.667, p < 0.0001).  Cases with >17 total repeats 
exhibited ~2.5 to 5 fold increase in variant 3 mRNA compared to cases with shorter 
repeats. Finally, analysis of the variant 3 to variant 2 ratio also reveals a striking positive 
correlation with larger repeat sizes (Figure 3.2e left, R
2
 = 0.849, p < 0.0001). Similar 
results were obtained when using the largest repeat allele as opposed to the total C9orf72 
repeat length (Figure 3.2b-e, right). However, total repeat number produced a stronger 
positive correlation to C9orf72 mRNA levels, supporting an additive effect of repeat size 
on expression.  
To confirm the positive relationship between C9orf72 repeat size and mRNA 
expression, we analyzed publicly available SNP eQTL data from the Genotype-Tissue 
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Expression (GTEx) Project
211
. Large C9orf72 repeat expansion mutations invariably 
occur within a 140kb haplotype block with a defined series of SNPs
116,212
.  The SNP 
rs3849942 is a commonly used marker for this haplotype block in which the G allele is 
associated with small non-expanded C9orf72 alleles, and the A allele is associated with 
both larger intermediate to full repeat expansions
43
. We observe the same trend in our 
CBD genomic DNA cohort where the rs3849942 A risk allele was associated with larger 
C9orf72 repeat sizes (Figure 3.2f). Using rs3849942 as a marker for longer/intermediate 
repeats (as full expansions are rare in unselected populations), we used GTEx data to 
determine if this SNP is associated with altered C9orf72 expression. We found that the 
risk allele is significantly associated with increased C9orf72 expression across numerous 
tissue types, with the largest effect size occurring in neural tissues (Figure 3.2g). 
Expanding the analysis to 20 haplotype defining SNPs
212
, we found that 12 of the SNPs 
on the risk allele are associated with increased C9orf72 expression in both the cortex and 
basal ganglia (Figure 3.2h ). In contrast, there were no significant eQTL SNPs that led to 
a decrease in expression. These results provide additional evidence that intermediate 
expansions lead to increased C9orf72 expression. 
 
CRISPR Editing of C9orf72 expansion size in iPSCs 
 In order to confirm the previous findings experimentally and to determine 
whether the risk haplotype versus the intermediate C9orf72 repeats themselves are 
driving increased C9orf72 gene expression, CRISPR/cas9 was used to modify the repeat 
size in previously characterized induced pluripotent stem cells (iPSCs) from a non-
diseased individual
202
. A repair template containing either 2 or 28 repeats was used to 
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alter the size of the repeat expansion in iPSCs that normally have alleles of either 2 or 6 
repeats (Figure 3.3a-b; Supplemental Figure 3.3). Clonal lines were derived by FACS and 
were screened for changes in repeat size and for the presence of the knocked-in allele by 
PCR followed by restriction enzyme digest (Figure 3.3b).  Genotype, including repeat 
size, was confirmed by repeat primed PCR (Figure 3.3c) and Sanger sequencing 
(Supplemental Figure 3.4).  Despite using a repair template with 28 repeats, several 
different iPSC clones with repeat sizes ranging from 23 to 28 were obtained.  Additional 
isogenic iPSC clones were also obtained with two or six C9orf72 repeats. 
Given that both neurons and glial cells are affected in CBD
194
, we used the dual SMAD 
inhibition method
203,213
 to differentiate edited iPSCs with intermediate C9orf72 
expansions and isogenic controls with small repeats into neural progenitor cells (NPCs) 
as determined by uniform expression of the NPC marker Pax6 (Supplemental Figure 3.5). 
RT-qPCR of these edited NPC lines showed a remarkably consistent pattern of higher 
C9orf72 mRNA expression in clones with intermediate C9orf72 repeats compared to 
isogenic controls with small repeats (Figure 3.3d). Consistent with the data from CBD 
post mortem brain tissue, we again saw no change in the amount of variant 2 mRNA 
(Figure 3.3e) but a robust increase in variant 3 mRNA levels in all intermediate C9orf72 
repeat cell lines (Figure 3.3f-g). This effect was not an artifact of neuronal differentiation, 
as undifferentiated iPSCs also exhibited increased C9orf72 mRNA levels (Supplemental 
Figure 3.6). Thus, these experiments demonstrate a causal relationship between 
intermediate C9orf72 expansions and increased C9orf72 mRNA levels.  
 
Intermediate repeat carriers do not have RNA foci or DPR pathology 
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 Full expansion carriers have characteristic neuropathology in post mortem brain 
and spinal cord tissue that includes nuclear RNA foci of G4C2 transcripts
43
 and 
aggregates of dipeptide repeat proteins (DPRs) that co-stain with p62
94
. Staining for 
DPRs using p62 antibody or DPR specific antibodies (GA, GP and GR) was carried out 
on 125 CBD cases in hippocampus and/or cerebellum, including 9 cases with 
intermediate repeats (repeat sizes 17-29, Figure 3.4a). Interestingly, all of these cases 
were negative for the aggregates typically seen in full expansion cases (Figure 3.4a).  
Additionally, RNA foci were not detected in CBD cerebellum tissues with intermediate 
repeats, nor were they detected in cases with low repeat numbers (Figure 3.4b). In 
comparison, full expansion FTD/ALS cases had abundant DPR aggregates together with 
RNA foci in ~18% of nuclei. Thus, the major pathologic hallmarks of full expansion 
carriers are not present in CBD cases, leading us to hypothesize that the underlying 
mechanisms of intermediate expansions and CBD risk may be distinct from the large 
repeat expansions that cause ALS/FTD. 
 
Elevated C9orf72 protein and global gene expression changes in intermediate repeat 
cell lines 
To test whether C9orf72 protein expression is higher in cells with intermediate 
repeats, protein expression was measured in isogenic repeat edited NPCs. NPC lines with 
intermediate repeats exhibited a consistent ~40% increase in C9orf72 protein levels when 
compared to isogenic low repeat number controls (Figure 3.5a-b). Thus, intermediate size 
repeat expansions increase both C9orf72 mRNA and protein levels.   
80 
 
 To determine whether overexpression of C9orf72 in the context of intermediate 
repeats alters expression of other genes, RNA sequencing was performed on 3 edited 
intermediate NPC lines and 3 low repeat isogenic control lines (Supplemental table 3.2, 
Supplemental file 1). We found 1,307 genes significantly downregulated (adjusted p-
value < 0.05 and fold change > 2) in intermediate repeat cell lines and 959 genes 
upregulated (Figure 3.5c). Next, overrepresentation analysis was performed on gene 
ontology pathways in the differentially expressed genes. Genes down regulated in 
intermediate repeat cell lines (Figure 3.5d) are highly enriched for metabolic processes, 
especially those involving nutrient catabolism. Genes upregulated in intermediate repeat 
cell lines (Figure 3.5e) are enriched in vesicle trafficking and protein degradation 
pathways including golgi vesicle transport, response to ER stress and autophagy. We then 
looked in more detail at specific genes within the most highly dysregulated biological 
processes. When categorizing vesicle trafficking genes according to their function
78
, there 
is modest increase in expression of numerous endosomal/lysomal genes, including 
C9orf72 (Figure 3.5f). Interestingly, there is a consistent and sizable decrease in 
expression of genes involved in secretory pathways in intermediate repeat cell lines, 
indicating a possible defect in vesicle secretion (Figure 3.5f). Additionally, key genes 
involved in autophagy are modestly increased in intermediates (Figure 3.5g). However, 
several genes that have been shown to regulate autophagy in response to nutrient 
starvation
214–216
 and ER stress
217
 such as TMEM74 and TMEM74B are markedly 
downregulated in intermediate repeat cells (Figure 3.5g), suggesting a defect in 
autophagy under stress conditions. Finally, we compared the differentially expressed 
genes in our dataset to previously published
81,83
 gene expression studies between control 
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(low repeat) and full expansion cells derived from ALS/FTD patients. Interestingly, we 
see a distinct group of dysregulated genes between control and intermediate repeat cells 
than between control and full expansion cells (Figure 3.5h), indicating that different 
processes are affected by intermediate expansions versus full expansions. 
 
Over-expression of C9orf72 impairs starvation-induced autophagy 
 Next, a cell culture model was used to further validate the observed changes in 
biological pathways in the RNA sequencing data and determine if these were in fact 
caused by C9orf72 over expression. Since C9orf72 is known to regulate 
autophagy
68,75,76,218
 and this pathway was altered in the RNA sequencing data, we 
generated an inducible isogenic HeLa cell line expressing a single-copy of human 
C9orf72 long isoform without the repeat expansion tagged with GFP and 6xHis-FLAG 
tag. The transgene expression level is comparable, i.e., 1:1, to that of endogenous 
C9orf72 and is under the tight control of tetracycline (Supplemental Figure 3.7 and 
207
). 
Importantly, the transgene also associates with the autophagy initiation complex, thereby 
confirming that the GFP-tagged C9orf72 recapitulates the known endogenous gene 
function
207
.  As a readout of autophagy, we utilized an LC3 (microtubule-associated 
protein light chain 3)-based assay (Figure 3.6a). During autophagosome assembly, LC3-I 
undergoes lipidation via conjugation with a phosphatidylethanolamine group to become 
LC3-II 
219,220
.  LC3-II is normally rapidly degraded during autophagy via fusion with the 
lysosome, but blocking lysosome fusion allows for accumulation of LC3-II to serve as a 
marker of autophagic activity
221
. Immunoblotting in C9orf72 overexpressing cells 
revealed that basal LC3-II levels are ~20% higher in C9orf72 overexpressing cells 
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compared to parental HeLa cells (lane NGM, normal growth medium, Figure 3.6b-c), 
indicating that either autophagosome production is increased or lysomal degradation of 
LC3-II is reduced under normal conditions. When autophagosome-lysosome fusion was 
blocked with chloroquine (CQ)
222
, LC3-II accumulates at a higher level in CQ-treated 
condition when compared to their untreated counterparts, and at a similar level between 
the parental HeLa and C9orf72 overexpressing cells (Lane NGM+CQ, Figure 3.6b-c).  
Interestingly, when autophagy was induced using nutrient-deficient medium, EBSS 
(Earle’s balance salt solution), the accumulation of LC3-II was reduced by ~40% in the 
C9orf72 overexpressing cells when compared with parental HeLa cells (Lane EBSS+CQ, 
Figure 3.6b-c), suggesting that C9orf72 overexpression blocks starvation-induced 
autophagy. To further corroborate the biochemical findings, a GFP-LC3 stable HeLa cell 
line
223
 was transfected with C9orf72 construct linked via P2A peptide to mCherry to 
better visualize the transfected cells. Consistent with the immunoblotting results above, 
~50% more LC3-II puncta were observed in the C9orf72 overexpressing conditions in 
normal growth media.  (NGM panel, Figure 3.6d-e). However, there was ~30% reduction 
of LC3-II puncta in C9orf72 overexpressing cells under starvation (EBSS+CQ panel, 
Figure 3.6d-e), again indicating that there is a failure of autophagy initiation in starvation 
conditions.   
To more accurately measure the actual autophagic flux or rate, a time course 
without and with chloroquine treatment was performed (Figure 3.7a). With the lysosomes 
blocked, LC3-II accumulated at a similar rate in C9orf72 overexpressing cells under 
normal conditions as the parental HeLa cells (Figure 3.7b-c, top blot). Under starvation 
conditions, however, the rate of accumulation was markedly reduced (Figure 3.7b-c, 
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bottom blot) compared to the parental HeLa cells. Taken together, these results suggest 
that C9orf72 overexpression promotes autophagy under nutrient rich conditions but limits 
the cell’s ability to induce autophagy during times of nutrient stress. 
 
Discussion 
 
In this study, we demonstrate that intermediate repeat expansions in C9orf72 may 
be a genetic risk factor for CBD, thus broadening the spectrum of neurodegenerative 
diseases implicated by this gene. This study highlights the importance of using autopsy 
confirmed cases to better understand the genetics of neurodegenerative diseases that have 
similar or overlapping clinical manifestations. Although intermediate repeats are found in 
only a small percentage of CBD patients, the magnitude of risk conferred by intermediate 
repeats is comparable or greater than other known genetic risk factors for CBD
224
. This 
study assembled the most CBD cases yet tested, and due to the rarity of CBD, a 
replication cohort is not yet available for follow-up analysis. While we established an a 
priori hypothesis based on the previously established but arbitrary cutoff of 17 repeat 
units or larger to define intermediate expansion carriers, our findings suggest that both 
CBD risk and C9orf72 expression increases in an additive manner with increasing repeat 
length where perhaps C9orf72 intermediate expansions could be defined as at least 10 
units. Interestingly, initial reports of C9orf72 repeat mutation cohorts, defined at that time 
as at least 30 repeats, included one case of autopsy-confirmed CBD
225
.  We did not detect 
any expansions larger than 29 repeats in our CBD cohort, and intermediate expansion 
carriers did not have the characteristic RNA foci and dipeptide repeat pathology seen in 
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full expansions. Future studies will need to further define the size threshold that 
determines whether carriers are more likely to develop risk for CBD versus ALS/FTD. 
C9orf72 joins a list of other repeat expansion containing genes in which the 
length of the repeat confers a pleiotropic effect on the disease phenotype. For instance, 
intermediate length CGG repeats in the gene FMR1 result in the neurodegenerative 
disease Fragile X-associated tremor/ataxia syndrome (FXTAS) linked to toxicity of 
repeat RNA
226
, whereas full expansions lead to near complete silencing of FMR1 and the 
neurodevelopmental disorder Fragile X Syndrome
50
. Similarly, intermediate CAG 
expansions in Ataxin-2 are a risk factor for ALS
227
, whereas full expansions cause 
spinocerebellar ataxia type 2
228
. For C9orf72, large expansions cause ALS/FTD
43,44
, 
whereas we demonstrate that intermediate expansions confer ~3.5 fold higher risk for 
CBD. Full expansions mutations in C9orf72 have been associated with reduction of 
C9orf72 gene expression and a gain of repeat associated pathology including nuclear 
repeat RNA accumulation and dipeptide repeat protein production
43,62,63,115
. In contrast, 
we show that intermediate expansions cause an increase in C9orf72 mRNA levels in both 
CBD post mortem cerebellum and knock-in isogenic neural cell lines. This mechanism is 
also supported by publicly available SNP eQTL data, which shows that numerous SNPs 
on the expansion haplotype are associated with increased C9orf72 expression.  Thus, it 
appears that maintaining proper levels of C9orf72 may be necessary for proper  neuronal 
function, with increased expression observed in CBD patients and decreased expression 
observed in ALS/FTD patients. 
C9orf72 is thought to function as Rab guanine exchange factor
55
, which 
participates in a host of vesicle trafficking pathways
65
. C9orf72 has been shown to 
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regulate endocytosis
56
, vesicle secretion
70
, intracellular trafficking
56,58,70,115
 and 
autophagy
67–69,76,218,229
. Indeed, we observe numerous gene expression changes in all of 
these vesicle trafficking pathways in knock-in NPCs with intermediate expansions. The 
large number of significant gene expression changes detected in this study is likely due to 
the depth of sequencing (~100 million reads/sample) and the use of isogenic CRISPR 
edited controls, which removes variability due to genetic background. Particularly 
striking changes were observed in genes involved in vesicle secretion and autophagy. The 
involvement of autophagy pathways in numerous neurodegenerative diseases has been 
well documented 
65
, and increased levels of C9orf72 may enhance CBD risk by 
disrupting autophagy pathways necessary for responding to stress. C9orf72 has been 
shown to regulate autophagy initiation through the ULK1 complex
67,75,207
, and we observe 
increased expression of autophagy initiation genes in the intermediate repeat knockin 
NPCs.  Interestingly, over expression of C9orf72 seems to increase autophagy initiation 
under normal conditions, but inhibits autophagy induction under nutrient stress. Several 
other studies have implicated C9orf72 as regulator of the cellular stress response
71,73,76,77
, 
and we observe dysregulation of genes involved in the ER stress response and nutrient 
biosynthesis pathways in intermediate repeat knockin NPCs. In particular, the gene 
TMEM74 and its paralog TMEM74B were highly downregulated in C9orf72 NPCs with 
intermediate repeats. TMEM74 has been shown to be a potent activator of autophagy 
induced via nutrient starvation
214
 and is thought to function via a unique pathway that 
does not require initiation via the canonical ULK1 autophagy initiation complex
215
.  This 
alternative initiation pathway may be affected by increased C9orf72 levels and could 
explain why we observe an autophagy defect in C9orf72 over expressing cells under 
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nutrient starvation. Future studies will need to further define the molecular mechanisms 
by which C9orf72 overexpression alters specific autophagy pathways. 
Overall, the findings presented here illustrate the complexity of C9orf72 repeat 
expansion mutations, with the length of expansion conferring risk for different 
neurodegenerative diseases via opposing mechanisms. Notably, the proportion of CBD 
cases with intermediate C9orf72 repeats is still relatively low (~4%) indicating that the 
overall genetic risk associated with intermediate repeats is modest.  Likewise, given that 
CBD is a rare disease, an otherwise normal individual harboring an intermediate repeat is 
unlikely to develop CBD.   Finally, these results indicate that autophagy pathways are 
dysregulated by elevated C9orf72 levels and suggest a link between C9orf72 expression 
and neurodegenerative disease.  
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Figure 3.1: C9orf72 repeat sizing of CBD. a) Example capillary electrophoresis traces 
of CBD cases measured from genomic DNA using a fluorescent PCR assay with 
genotypes of 2,2 (top), 2,18 (middle) or 9,20 (bottom). b) Summary statistics for repeat 
size screening of CBD cases (n = 708 alleles) and previously published controls (n = 
11,774 alleles)
123
.  Fisher’s exact test: OR = 3.59, 95% CI = 1.80 – 6.65, p = 0.000238. c) 
Allele frequencies of repeat sizes in CBD cases and controls. The number of alleles in the 
CBD cohort for each size is depicted above the bars. d) Results of Fisher’s exact test 
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between CBD cases and controls at each allele size cutoff. Dotted gray line represents p < 
0.05 significance level.  
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Figure 3.2: Effect of intermediate repeats on C9orf72 expression. a) Diagram of the 
C9orf72 locus with mRNA and protein isoforms. Transcription start sites (TSS) are 
labeled for each mRNA variant on the genomic DNA. Colored arrows on the mRNA 
depict primers used for RT-qPCR. b) Correlation between total C9orf72 repeat size (left) 
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or largest allele (right) and C9orf72 mRNA levels from all variants measured by RT-
qPCR using RNA from CBD patient cerebellum (Total repeats: n = 29, R
2
 = 0.276, p = 
0.0034; Largest allele: n = 29, R
2
 = 0.1613, p = 0.0308). Data is normalized to samples 
with 4 total repeats.  c) Correlation between total C9orf72 repeat size (left) or largest 
allele (right) and variant 2 mRNA levels (Total repeats: n = 29, R
2
 = 0.00496, p = 0.717; 
Largest allele: n = 29, R
2
 = 0.04432, p = 0.2730). d) Correlation between total C9orf72 
repeat size (left) or largest allele (right) and variant 3 mRNA levels (Total repeats: n = 
29, R
2
 = 0.667, p < 0.0001; Largest allele: n = 29, R
2
 = 0.4874, p < 0.0001). e) 
Correlation between total C9orf72 repeat size (left) or largest allele (right) and the variant 
3 mRNA to variant 2 mRNA ratio (Total repeats: n = 29, R
2
 = 0.849, p < 0.0001; Largest 
allele: n = 29, R
2
 = 0.8869, p < 0.0001). f) Genotyping results for rs3849942 in the CBD 
patient genomic DNA cohort (n = 708 alleles). The A allele is associated with 
intermediate and full length repeat expansions. g) SNP eQTL data from the Gtex project 
showing the effect of rs3849942 on C9orf72 expression in basal ganglia (left, p = 9.00E-
07) and tibial nerve (right, p = 2.80E-16). For box plots, center line indicates median, 
boxes are upper and lower quartiles, error bars are standard error of the mean. Numbers 
of samples are indicated below each group. h) Normalized GTEx eQTL effect size from 
cortex and basal ganglia on C9orf72 expression for all 20 SNPs in the consensus repeat 
expansion risk haplotype (from Mok et al. 2012
212
). * indicates SNPs with a significant 
effect on C9orf72 expression. Red dotted line indicates the location of the C9orf72 repeat 
expansion. 
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Figure 3.3: CRISPR/cas9 knock-in of intermediate repeats into iPSCs. a) Diagram of 
C9orf72 genomic locus and double stranded repair templates used for knocking in 
intermediate repeats. Black triangle represents the CRISPR/cas9 cut site. Black arrows 
indicate the PCR primers used in (b). Red boxes indicate the G4C2 repeat. Blue boxes 
indicate the 2 bp substitution included in the repair templates to mutate the Cas9 PAM 
site and generate a PvuII restriction enzyme site. b) PCR (top) and PvuII digest (bottom) 
of CRISPR edited iPS cell lines using PCR primers spanning the CRISPR cas9 cut site 
and repeat expansion. Digestion of the PCR product indicates that HDR occurred. c) 
Capillary electrophoresis traces of repeat primed PCR from CRISPR edited iPSCs. d-g) 
RT-qPCR from the indicated variants of C9orf72 from neural progenitor cells 
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differentiated from CRISPR edited iPSCs. Light bars correspond to low repeat lines 
while black bars correspond to intermediate repeat lines. N = 3 biological replicates per 
cell line; ANOVA (All variants: F = 18.3, p = 0.0001; Variant 2: F= 2.9, p = 0.08; 
Variant 3: F = 216.0, p < 0.0001; V2/V3: F = 460.0, p < 0.0001) followed by Bonferroni 
post hoc test between low and intermediate repeat cell lines. **p < 0.01, ***p < 0.001, 
****p < 0.0001. Error bars are standard error of the mean.
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Figure 3.4: Absence of repeat pathology in intermediate expansion cases. a) 
Representative Immunohistochemistry images of non-expanded control (n=4 cases) or 
non-expanded CBD (n = 116 cases), intermediate expansion CBD (n = 9 cases), and full 
expansion FTD/ALS (n = 5 cases) post mortem cerebellar samples using anti-GA or p62 
antibodies. Intermediate expansion carriers were also negative for GP/GR aggregates. 
Scale bar 10μm. b) Representative fluorescence in situ hybridization images of non-
expanded control (n=4 cases) or non-expanded CBD (n = 12 cases), intermediate 
expansion CBD (n = 5 cases), and full expansion FTD/ALS (n = 5 cases) post mortem 
cerebellar samples using a probe complimentary to the G4C2 repeat.  Scale bar 5μm. 
 
94 
 
 
Figure 3.5: Elevated C9orf72 protein levels and gene expression changes in 
intermediate repeat NPCs. a) Western blot of protein expression from CRISPR edited 
NPCs. N = 2 low repeat and 3 intermediate repeat number cell lines. C9orf72 antibody 
was validated in HEK293T cells transfected with C9orf72 overexpression plasmid (Lanes 
1-2). Representative blot of 2 technical replicates is shown. b) Quantification of C9orf72 
protein levels from repeat edited NPCs. Protein expression was normalized to GAPDH as 
a loading control and the average of 2 technical replicates is reported. N = 2 low repeat 
and 3 intermediate repeat number cell lines. Two tailed t-test, p = 0.0145. Error bars are 
standard error of the mean. c) RNA sequencing analysis of 3 low repeat NPC lines (max 
repeat size 2 or 6) and 3 intermediate repeat (max repeat size 23, 27 or 28) NPC lines. 
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Differentially expressed genes with an adjusted p-value < 0.05 and greater than 2 fold 
change are depicted as red dots. d-e) Overrepresentation analysis of biological processes 
on differentially downregulated genes (d) or upregulated genes (e) in NPCs with 
intermediate repeats. Labels highlight the top 10 most significant biological processes. f) 
Changes in gene expression of genes involved in vesicular trafficking. All genes shown 
are significantly differentially expressed (adjusted p < 0.05) between low repeat and 
intermediate repeat NPCs. g) Changes in gene expression of genes involved in 
autophagy. All genes shown are significantly differentially expressed (adjusted p < 0.05) 
between low repeat and intermediate repeat NPCs. h) Comparison of overlap in 
differentially expressed genes between low repeat NPCs versus intermediate repeat NPCs 
(this study) or low repeat vs full expansion neurons from patient derived iPSCs from two 
previous studies 
81,83
. Only genes with adjusted p < 0.05 and fold change > 2 were used in 
this comparison.  
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Figure 3.6: Autophagy defects in inducible C9orf72 over-expressing cells 
a) Schematic of experimental procedure for LC3-II protein detection in C9orf72 HeLa 
stable cells. b)  Representative western blot showing LC3-II expression levels of parental 
HeLa cells and C9orf72 cells first treated with treated with tetracycline to induce C9orf72 
transgene expression then with EBSS and/or CQ for 1 hour. c)  Bar  chart  corresponding  
to  (b)  showing  pooled  data  of  LC3-II  protein  levels expressed  as  fold  change  over  
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parental  HeLa  cells in normal growth media without CQ treatment.  Data represents 
three independent experiments with * p<0.05, Student’s t-test.  d)  Schematic  of  
experimental procedure  for  the  detection  of  LC3-II  puncta  using  fluorescence  
microscopy  in  parental HeLa  cells overexpressing  GFP-LC3  and  mCherry  (control)  
or  C9orf72-P2A-mCherry  plasmids.  The cells were treated with NGM, EBSS, 
EBSS+CQ or NGM+CQ for 2 hours and green puncta associated with GFP-LC3 in 
mCherry-overexpressing cells were analyzed using ImageJ particle count. At least 25 
cells were analyzed per treatment group. Scale bar = 20 µm. e) Bar chart corresponds to 
the average LC3 puncta count in (d) with * p < 0.05, Student’s t-test. Error bars represent 
standard error of the mean (S.E.M).
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Figure 3.7: Kinetics of starvation induced autophagy in C9orf72 over-expressing 
cells. a) Schematic of time-course experiments on autophagy in C9orf72 HeLa stable 
cells. b) Representative western blot showing LC3-II expression levels of parental HeLa 
cells and C9orf72 cells first treated with tetracycline to induce C9orf72 transgene 
expression then with either normal growth media (NGM)+CQ or EBSS+CQ for 0, 1, 2, 
and 3 hours. c) Time course chart corresponding to (b) showing pooled data of LC3-II 
protein levels expressed as fold change over respective controls, i.e. parental HeLa cells 
or C9orf72 cells grown in normal growth media without CQ treatment. Data represents 
three independent experiments with error bars representing standard error of the mean 
(S.E.M). 
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Supplemental Figures and Tables 
 
 
 
 
Supplemental Figure 3.1: Repeat Expansion sizes in the CBD post mortem cerebellum 
cohort. Repeat sizes from CBD post mortem cerebellum detected using fluorescent PCR 
followed by capillary electrophoresis. N = 47 cases. 
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Supplemental Figure 3.2: DNA methylation analysis at the C9orf72 promoter of CBD 
post mortem cerebellum cohort and comparison to full expansion cases. DNA 
methylation was measured using HhaI digest followed by qPCR on CBD cases (n = 47) 
and full expansion ALS/FTD cases (n= 20). Within the CBD case group, there is no 
significant association between repeat size and DNA methylation of C9orf72 (R
2
 = 
0.01012, p = 0.5010).  
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C9orf72 Homologous Repair template (5’ to 3’) 
CCGCTAGGAAAGAGAGGTGCGTCAAACAGCGACAAGTTCCGCCCACGTAAAAGATGACGCTTGGTGTGTCA
GCCGTCCCTGCTGCCCGGTTGCTTCTCTTTTGGGGGCGGGGTCTAGCAAGAGCAGGTGTGGGTTTAGGAGG
TGTGTGTTTTTGTTTTTCCCACCCTCTCTCCCCACTACTTGCTCTCACAGTACTCGCTGAGGGTGAACAAG
AAAAGACCTGATAAAGATTAACCAGAAGAAAACAAGGAGGGAAACAACCGCAGCCTGTAGCAAGCTCTGGA
ACTCAGCTGTCGCGCGCTAGGGGCCGGGGCCGGGGCGTGGTCGGGGCGGGCCCGGGGGCGGGCCCGG
GGCGGGGCTGCGGTTGCGGTGCCTGCGCCCGCGGCGGCGGAGGCGCAGGCGGTGGCGAGTGGGTGAGTGAG
GAGGCGGCATCCTGGCGGGTGGCTGTTTGGGGTTCGGCTGCCGGGAAGAGGCGCGGGTAGAAGCGGGGGCT
CTCCTC 
 
Supplemental Figure 3.3: Homologous template and gRNA sequence used to edit the 
endogenous C9orf72 repeat expansion size. Homologous template containing either 2 or 
28 G4C2 repeat units was cloned via PCR and inserted into P-gem Easy T vector. The 
20bp CRISPR gRNA sequence is underlined and the 2 bp mutation which destroys the 
PAM site and introduces a PvuII restriction enzyme site is highlighted in red. The G4C2 
expansion site is in bold (shown here is 2 repeat units).  
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Supplemental Figure 3.4: Sanger sequencing of repeat edited iPSCs. Representative 
chromatograms of CRISPR edited iPSCs that were PCR cloned and Sanger sequenced. 
All CRIPSR edited cell lines included in this study were matched to have the same 8 bp 
deletion on the non-repeat edited allele, likely due to non-homologous end joining. 
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Supplemental Figure 3.5:  Characterization of iPSC derived neural progenitor cells. 
Immunofluorescence images of day 12 post neural induction CRISPR edited NPCs 
stained with either pax6 (NPC marker) or Oct4 (iPSC marker).  The number separated by 
a comma indicates repeat sizes of each allele in the NPC cell lines. 
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Supplemental Figure 3.6:  C9orf72 variant 3 mRNA levels from undifferentiated, repeat 
edited iPSCs. 1 way ANOVA followed by Bonferroni multiple comparison test. ****p < 
0.0001. All intermediate repeat cell lines are significantly different than both low repeat 
controls 
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Supplemental Figure 3.7: Expression of C9orf72 transgene is comparable to the 
endogenous C9orf72 and is induced by tetracycline. a) Immunoblots of parental HeLa 
cells and the inducible isogenic C9orf72 cells used in this study. Both groups were 
treated with tetracycline for 18 hours. A polyclonal antibody (Santa Cruz Biotechnology, 
sc-138763) was used to detect the endogenous C9orf72 (black arrowhead) and the 
C9orf72 transgene (green arrowhead). The level of transgene is comparable to 
endogenous C9orf72 and the levels of endogenous C9orf72 are similar between parental 
HeLA cells and C9orf72 inducible cells. b) Immunoblots of C9orf72 transgene with or 
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without tetracycline induction. Inducible isogenic C9orf72 cells were cultured without (-) 
or with (+) tetracycline and subjected to GFP-immunoprecipitation to enrich for C9orf72 
transgene. Input and GFP-immunoprecipitants were probed with FLAG antibody to 
detect C9orf72 transgene. C9orf72 transgene only be detected after tetracycline 
treatment.  
 
 
 
  
Table 3.S1: Primers and CRISPR gRNAs  
Forward Primer Sequence  Reverse Primer Sequence Assay 
6FAM-CAAGGAGGGAAACAACCGCAGCC GCAGGCACCGCAACCGCAG Sizing of C9orf72 Repeats 
6FAM-AGTCGCTAGAGGCGAAAGC TACGCATCCCAGTTTGAGACG 
Repeat Expansion 
Detection 
TACGCATCCCAGTTTGAGACGGGGGCCGGGGCCGGGGCCGGGG 
 
Repeat Expansion 
Detection 
CCCACTTCATAGAGTGTGTGTTG TTCCATTCTCTCTGTGCCTTC 
Total C9orf72 mRNA (all 
variants) 
CGGTGGCGAGTGGATATCTC TGGGCAAAGAGTCGACATCA C9orf72 variant 2 mRNA 
GCAAGAGCAGGTGTGGGTTT TGGGCAAAGAGTCGACATCA C9orf72 variant 3 mRNA 
GAGGAGAGCCCCCGCTTCTAC 
 
CCGCTAGGAAAGAGAGGTGCG 
 
Template cloning and 
HDR analysis of repeat 
edited iPSCs 
CACCGTGTAGCAAGCTCTGGAACTC aaacGAGTTCCAGAGCTTGCTACAC 
CRISPR gRNA sequences 
for repeat editing 
CAGTGTGAAAATCATGCTTGAGAGA TTTGTGCTTGGTAGGCAGTG DNA methylation analysis 
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Table 3.S2: RNA sequencing of intermediate repeat NPCs raw read counts 
Sample Repeat Size Total Reads 
Short Repeat 1 2,6 109337673 
Short Repeat 2 2,2 108537553 
Short Repeat 3 2,6 118024548 
Intermediate Repeat 1 2,23 125527873 
Intermediate Repeat 2 6,28 121998215 
Intermediate Repeat 3 27,27 131039648 
 
 
 
Table 3.S3: Evaluation of C9orf72 Risk haplotype marker rs3849942 A in CBD 
cases vs control populations 
Cohort 
rs3849942 A Risk Allele 
Frequency 
Chi Square Test 
Odds Ratio (95% 
CI) 
CBD cases 159 / 698 (22.78%)   
Controls from Beck et 
al. 2013 
2,597 / 10,400 
(24.97%) 
X
2
 = 1.568, p = 
0.2105 (n.s.) 
0.8863 
(0.7385-1.064) 
Gobal populations 
(dbSNP) 
35,048/162,186 
(21.6%) 
X
2
 = 0.4124, p = 
0.5207 (n.s.) 
1.064 (0.8913-
1.271) 
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Table 3.S4: Repeat sizes of CBD cases with intermediate expansions  
Case Number Repeat Size Allele 1 Repeat Size Allele 2 
1 2 29 
2 2 26 
3 2 22 
4 2 22 
5 6 21 
6 6 21 
7 9 20 
8 2 18 
9 5 17 
10 2 17 
11 14 17 
12 2 17 
13 2 17 
 
Table 3.S5: Comparison of CBD cohort vs Theuns. et al 2014 controls at each allele 
cutoff 
Repeat Size Cutoff P-Value (Fisher Exact Test) Odds Ratio 
3 0.876300 0.9853727 
4 0.640200 0.9612321 
5 0.638300 0.9609401 
6 0.700700 0.9653403 
7 0.963300 1.006105 
8 0.499400 1.064384 
9 0.209900 1.182729 
10 0.026040* 1.359480 
11 0.108800 1.292946 
12 0.032910* 1.498095 
13 0.073220 1.489279 
14 0.128100 1.491891 
15 0.061270 1.757263 
16 0.004179** 2.512414 
17 0.0002376**** 3.591016 
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Chapter 4: Conclusions and Future Directions 
 
This thesis explored several different pathways related to how repeat expansions 
in C9orf72 contribute to neurodegenerative disease. First, we developed a novel method 
of targeted methylation in order to model DNA hypermethylation that is observed in 
ALS/FTD patients with the C9orf72 repeat expansion. This work led to several important 
conclusions regarding the relationship between DNA damage and DNA methylation.  
DNA methylation is linked to DNA double strand break repair 
 
 It has long been thought that DNA methylation and DNA repair pathways were 
related due to the fact that chromosomal breaks correlate with changes in DNA 
methylation
131
. This idea was bolstered by evidence from reporter constructs that double 
strand breaks can directly induce DNA methylation
167–169
. Prior to this work, however, no 
study had shown that this process also occurs at endogenous genes. It’s possible that 
methylation of exogenous DNA could be a defense response against foreign DNA such 
as viruses or transposable elements. The work presented here shows that methylation 
following DNA damage also occurs at endogenous genes and thus is a more generalized 
response than originally realized. This finding may help explain why DNA methylation at 
specific sites increases with age
132
, as DNA damage due to oxidative stress is known to 
increase with age as well
230
. Future studies using multiplexed CRISPR gRNAs targeted 
to CpG islands could determine which loci genome-wide are prone to DNA methylation 
following DNA cleavage. These results would have important implications for cancer and 
other aging related diseases.  
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Another important finding relating to DNA methylation and DNA repair 
pathways is that methylation marks can be copied from an exogenous repair template into 
the genome. This was dependent on the process of homology directed repair (HDR), and 
the efficiency of methylation correlated with the length of the repair template. This 
process was also dependent on DNMT1, DNMT3a, DNMT3b and UHRF1. It was 
initially surprising that both the maintenance methyltransferase enzyme (DNMT1) and 
the de novo methyltransferase enzymes (DNMT3a/3b) were all involved in copying of 
methylation during HDR. However, it has been suggested that the methyltransferase 
enzymes have more overlapping functionality than previously realized
231
. Additionally, 
we did not determine the exact contribution of these enzymes to methylation via the 
different repair pathways. It is possible that the de novo methyltransferases are 
responsible for targeting methylation following NHEJ, whereas the DNMT1/UHRF1 
complex is responsible for copying methylation from the repair template. Future 
experiments will need to clarify this point. 
 Additionally, it is unclear why only ~50% of CpGs are methylated in the 
endogenous gene following HDR. One possibility is that methylation is not copied during 
a subset of repair events. This is possible if some DNA is repaired via the non-canonical 
synthesis dependent strand annealing pathway (SDSA). SDSA differs from canonical 
HDR in that it only utilizes limited synthesis from one strand of the repair template rather 
than copying from both strands
166,232
. Since copying of methylation is likely to occur 
during DNA synthesis from the methylated template, repair via SDSA would restrict 
copying of methylation to small regions around the break site. Future studies should 
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explore the sub-pathways of HDR more closely in order to improve efficiency of 
methylation following HDR. 
Hypermethylation of the C9orf72 promoter leads to gene silencing 
 
Another key finding from Chapter 2 is that DNA methylation of the C9orf72 
promoter leads directly to a gain in histone H3K9 trimethylation and a reduction of 
C9orf72 mRNA levels in ALS patient derived iPS cells. Furthermore, the largest 
reduction in mRNA levels occurred from the transcription start site closest to the CpG 
island, suggesting that the proximity of DNA methylation to the transcription start site 
may influence transcriptional activity.  This transcript (V3) also contains the repeat 
expanded RNA, and thus preferential reduction of this transcript may ameliorate the gain 
of function toxicity associated with the expanded RNA.  Future studies using this newly 
established cellular model of DNA hypermethylation are needed to better understand how 
a reduction in C9orf72 mRNA affects the balance between a loss of normal C9orf72 
protein function and inhibition of the toxic gain of function pathway.  
HARDEN can be applied for targeted methylation of APP  
 
A major unanswered question is whether HARDEN is a general method that can 
be applied to other genomic loci. It is known that genes with repeat expansions are prone 
to DNA methylation, so it is possible that C9orf72 might be more amenable to targeted 
DNA methylation. To determine if HARDEN can be applied to another locus besides 
C9orf72, we targeted a CpG island in the promoter region of APP. APP encodes amyloid 
precursor protein, a key protein involved in Alzheimer’s disease (AD) pathogenesis233. 
112 
 
APP is cleaved by proteases to generate amyloid beta peptides, which are a major 
component of amyloid plaques found in AD patient brain
233
. Amyloid beta production is 
thought to play a central role in AD pathogenesis, as mutations in APP that increase 
amyloid beta levels are known to cause dominantly inherited early-onset AD
234
. Several 
studies have investigated the DNA methylation status of the CpG island upstream of APP 
but have come to differing conclusions as to whether APP is differentially methylated in 
AD patients
235–238
. Thus, it may be beneficial to generate cellular models of DNA 
methylation at this locus to determine the effects of DNA methylation on APP 
expression.  
As a proof of principle, we applied the HARDEN system to APP by inducing a 
double strand break with Cas9 and providing a methylated repair template (Figure 4.1, 
A). The repair template also includes a 12 base pair mutation that allows for PCR 
amplification of only the DNA that has undergone HDR using the repair template (Figure 
4.1, B). Bisulfite cloning of amplicons repaired with an unmethylated or methylated 
template was then carried out to assess the DNA methylation pattern of repaired DNA 
(Figure 4.1, C). This analysis revealed that DNA repaired with the methylated template is 
highly enriched for methylation, with the CpG sites closest to the cut site exhibiting 
levels of methylation exceeding 50% (Figure 4.1, C-D). In some clones, methylation was 
copied more than 500 base pairs downstream from the cut site (Figure 4.1, C-D). In sum, 
~45% of amplicons (10/22) gain dense DNA methylation when repaired with a 
methylated template, compared to no amplicons (0/23) repaired with the unmethylated 
template (Figure 4.1, E). These results indicate that DNA methylation can be copied 
during HDR and confirm that HARDEN is a generalizable method that can be applied to 
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other genes besides C9orf72. Future work using these epigenetically edited cells could 
determine whether hypermethylation of this CpG island reduces APP expression and 
downstream amyloid beta production.  
 
Figure 4.1: Targeted DNA methylation of APP via HARDEN. A) Diagram of APP gene locus 
showing CpG island, gRNA targeting site (black triangle) and bisulfite primers (Red and black arrows) 
used to amplify only DNA that incorporates a 12bp mutation (red box) from the template. B) Bisulfite PCR 
of HEK293T cells transfected with No gRNA plasmid, APP gRNA + unmethylated template or APP gRNA 
+ methylated template. n = 2 biological replicates. Primer location is indicated in (A). C) Bisulfite 
sequencing of cloned amplicons from (B). Each column represents a CpG site in the ~600bp amplicon. 
Grey boxes indicate unmethylated cytosines whereas black boxes represent methylated cytosines. n = 23 
sequences for APP gRNA+ unmethylated template group and n = 22 sequences for APP gRNA+ 
methylated template group. D) Quantification of mean methylation at each CpG site in the amplicon (73 
total CpG sites) depicted in (C). n = 23 sequences from unmethylated template group and n = 22 sequences 
from methylated template group. E) Number of highly methylated amplicons (>20% methylation) from 
bisulfite sequencing depicted in (C). n = 23 sequences for unmethylated template group and n = 22 for 
methylated template group. 10 amplicons are highly methylated in the methylated template group vs 0 
amplicons in the unmethylated template group. ***p = 0.0002; Fisher’s exact test (two sided).  
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In chapter 3, we explore the genetic risk associated with C9orf72 intermediate 
repeat expansions and how this relates to gene expression. Prior to this study, there was 
no clear indication of whether intermediate repeats in this gene were a risk factor for 
neurodegenerative disease. This study was not only the largest exploration of genetic risk 
for the neurodegenerative disease corticobasal degeneration (CBD), but it also revealed 
key insights into the molecular pathways that may be driving disease risk. 
C9orf72 intermediate repeat expansions are a risk factor for corticobasal 
degeneration 
 
 Perhaps the most important finding of chapter 3 was that intermediate repeats in 
C9orf72 are a risk factor for corticobasal degeneration. Prior to this work, there was 
conflicting evidence as to whether C9orf72 was a risk factor for other neurodegenerative 
diseases such as Parkinson’s disease125,126. We found that expansion carriers with 
intermediate repeats ranging from 17-30 units have more than 3-fold higher risk for CBD. 
Importantly, our study also suggests a new definition of what should be considered an 
“intermediate” size repeat expansion in C9orf72, as we observe increasing risk for CBD 
beginning at just 10 repeats. This work also highlights the importance of an autopsy 
confirmed cohort for genetic analysis of neurodegenerative diseases that have similar 
clinical characteristics. It remains important to note, however, that CBD is a rare disease 
and thus a given intermediate expansion carrier in the general population has relatively 
low risk for developing CBD. The rarity of CBD made it impossible to assemble a large 
enough replication cohort for this association. When more cases become available in the 
future, a replication study should be conducted.  
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Intermediate length repeat expansions increase C9orf72 expression 
 
Another significant finding in this thesis work is that intermediate length repeat 
expansions have the opposite effect on C9orf72 expression as the full length expansions. 
It is well established that the full length expansions that cause ALS/FTD result in 
decreased C9orf72 mRNA and protein levels
44,62,63,115
. Our work shows that C9orf72 
expression is actually increased in intermediate expansion carriers. This was true in both 
patient post mortem brain tissue and in knock-in isogeneic neural progenitor cells. 
Furthermore, it appears that expression increases with increasing total repeat number in 
an additive manner. This corresponds well with the observation that CBD risk also 
increases with increasing repeat number and suggests that increased C9orf72 expression 
may be driving disease risk (Figure 4.2).  
 
Figure 4.2: Effect of C9orf72 repeat size on expression and disease risk. C9orf72 expression 
increases linearly from low repeats (2-8 units) to intermediate repeats (10-30), but decreases in 
full expansion carriers. Risk for CBD increases with increasing repeat number (up until 30 
repeats), whereas ALS/FTD develops in carriers with ~70 repeats or more. CBD risk may result 
from decreased tau clearance in intermediate repeat cells due to autophagy defects. ALS/FTD 
may be driven by toxic RNA and protein species in the context of low C9orf72 expression.  
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This work reinforces previous findings in carriers with intermediate GCC repeats 
in the FMR1gene. In this gene, individuals with 55-200 repeats are at risk for the 
neurodegenerative disease fragile X-associated tremor/ataxia syndrome (FXTAS)239. 
FXTAS patients exhibit increased FMR1 expression whereas larger expansions result in 
epigenetic silencing and the neurodevelopmental condition fragile X syndrome
50,240–242
.  
Future studies should delve into the mechanisms underlying how intermediate expansions 
cause upregulation of C9orf72. One possibility is that the GC rich nature of intermediate 
repeats promotes transcription from upstream transcription start sites (TSS) that are more 
active. Indeed, our data suggests that the increase in C9orf72 mRNA levels is driven 
primarily through an increase in variant 3 abundance, which is normally the minor 
isoform and has a TSS upstream from the repeat expansion. A similar mechanism has 
been observed in FXTAS patients, where a shift to an upstream TSS results in higher 
levels of transcription
240,243
.  Another possibility is that intermediate expansions lead to 
increased mRNA stability of repeat containing transcripts, although this is not observed 
in FXTAS
240
. Future work should clarify whether increased levels of C9orf72 are due to 
enhanced transcription, reduced mRNA degradation or increased translation.  
Increased C9orf72 expression disrupts autophagy 
 
A final key finding from this thesis work is that increased expression of C9orf72 
results in an ablated autophagy response under nutrient stress conditions. We found that 
knock-in neuronal progenitor cells with intermediate repeats exhibit gene expression 
changes in key autophagy and endo-lysosomal pathways. The dysregulated genes also 
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included genes responsible for promoting autophagy under stress conditions. These 
results were reinforced by experiments in a C9orf72 over-expression cell culture model. 
We found that C9orf72 over-expression promotes autophagy under normal conditions but 
actually blocks autophagy induction during nutrient starvation.  These finding suggest a 
model where proper levels of C9orf72 are required for an appropriate stress response. 
While we only examined the response to nutrient deprivation, other studies have 
implicated C9orf72 in the response to other stressors including ER stress, oxidative stress 
and heat shock
71,76,77
.  Thus, an ablated stress response in the context of aging or other 
insults may underlie the neurodegenerative disease risk associated with C9orf72 
intermediate expansions. Future studies will need to further define how differing levels of 
C9orf72 can both promote and inhibit autophagy under different conditions.  
C9orf72 expression and tau aggregation  
 
A final area for future investigation is to determine how increased expression of 
C9orf72 relates to the disease pathology seen in CBD. The major pathology found in 
CBD patients is neuronal and astrocytic tau aggregates
244
. In preliminary experiments, we 
asked whether increasing C9orf72 expression may alter tau aggregation. We utilized a 
previously developed
245
 “tau biosensor” cell line that stably expresses a mutant tau repeat 
domain (P301S) fused to fluorescent reporters. When seeded with purified tau from post 
mortem brain, the tau reporters aggregate and generate a FRET signal that is detected by 
flow cytometry (Figure 4.3, A)
245
. We overexpressed C9orf72 protein at either low or 
high levels in these cells using constructs devoid of the intronic G4C2 repeat domain and 
transduced them with tau from CBD patient post-mortem brain (Figure 4.3, B). After 
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measurement of FRET via flow cytometry, we found that FRET intensity appeared to 
increase in a dose dependent manner with increasing amounts of C9orf72 over-
expression (Figure 4.3, C) but was only significantly higher when using a codon 
optimized construct with large amounts of over-expression. These results suggest that 
high levels of C9orf72 over-expression may promote increased tau aggregation. Future 
studies in more physiological models of tau pathology will be needed to determine 
whether this effect is specific for C9orf72 and represents a real mechanism of disease 
risk. 
 
Figure 4.3: Effect of C9orf72 over-expression on tau aggregation. A) Overview of tau 
biosensor cells. HEK293T cells stably express mutant (P301S) tau repeat domain fused to a 
fluorescent protein. When seeded with tau from CBD patient brain, tau aggregation can be 
measured as a FRET signal by flow cytometry. B) Western blot of C9orf72 in tau biosensor cells 
that were transfected with either a WT or HA-tagged codon optimized C9orf72 encoding plasmid. 
C) Normalized FRET signal measured by flow cytometry of tau biosensor cells transfected with 
empty vector or C9orf72 overexpression constructs. Data was normalized to empty vector 
control. n = 4 experiments. 1 way ANOVA (p = 0.0014) followed by Bonferroni post hoc test. 
**p < 0.01.  In collaboration with Jessica Phan. 
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Final Remarks 
The work presented here highlights the complexity of neurodegenerative diseases 
and the challenges faced by researchers in trying to define the underlying molecular 
mechanisms. Here, we show that mutations within a single gene that are known to cause 
ALS and FTD can also serve as a risk factor for a third neurodegenerative disease, CBD. 
Furthermore, the length of the repeat expansion and the epigenetic status of the locus 
serve as disease modifiers, thereby adding additional complexity. Despite this, our work 
demonstrates that common molecular pathways emerge in these diseases such as protein 
aggregation, cellular stress responses, autophagy and regulation of gene expression. We 
hope that the novel method of targeted DNA methylation presented here and the new 
insights into intermediate C9orf72 repeat expansions may further the research 
community’s efforts to find cures for these fatal diseases.  
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APPENDIX 
Protocols 
CRISPR gRNA Cloning 
1. Design gRNAs and add BbsI overhangs:  
a. Add CACCG on 5’ end of top oligo 
b. Add C on 3’ end and CAAA on 5’ end of bottom oligo 
2. Resuspend oligos in milliqH20 to 100uM 
3. Oligo Annealing/Phosphorylation Reaction: 
Component Amount (ul) X 4 reactions 
x100uM sgRNA oligo Top Strand 1 - 
100uM sgRNA oligo Bottom Strand 1 - 
10X NEB T4 DNA Ligation Buffer 1 4 
NEB T4 PNK 1 4 
Milliq H2O 6 24 
TOTAL: 10ul 8ul + 1ul F + 1ul R 
Thermocycler program: CRISPR Anneal 
Cycling Conditions: 37⁰ for 30mins, 95⁰ for 5mins, Ramp to 25 at 5⁰/s (2.5% on Veriti thermocycler) 
 
4. Dilute reaction above 1:200 in H2O (Note: diluted reaction can be stored at -20) 
5. Ligation Reaction: 
Component Amount (ul) X 4 reactions 
Cas9 Plasmid at 50ng/ul 2 8 
Diluted guide oligos from step 4 2 - 
10X Cutsmart Buffer 2 8 
10mM DTT 1 4 
10mM ATP 1 4 
NEB BbsI (5U/ul) 1.25 5 
NEB T4 DNA ligase 1 4 
H20 9.75 39 
TOTAL: 20 18ul +2ul oligo 
Thermocycler Program: CRISPR Ligation 
Cycling Conditions: [37⁰ for 5mins, 21⁰ for 5mins ] x 6 cycles 
 
6. Plasmid Safe Reaction: 
Component Amount (ul) X 4 reactions 
Ligation reaction from above 11 - 
10X Plasmid Safe Buffer 1.5 6 
10mM Plasmid Safe ATP Solution 1.5 6 
Plasmidsafe Exonuclease 1 4 
TOTAL: 15 4ul + 11ul ligation rxn 
Thermocycler Program: Plasmidsafe 
Cycling Conditions: 37⁰ for 30mins, 70⁰ for 30mins 
 
7. Proceed to transformation or store at -20⁰ 
8. Transformation: 
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a. Add 2ul of plasmidsafe reaction to 25ul of thawed NEB Turbo competent cells (NEB) 
b. Incubate on ice 30mins 
c. Heatshock at 42⁰ for 30 sec 
d. Incubate on ice 5 mins 
e. Add 750ul of SOC and incubate in shaker at 37⁰ for 1 hour 
f. Dilute 1:3 and plate 60ul on LB amp plate 
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DNA methylation detection via MSRE-qPCR   
 
Reagents:  
 HhaI (NEB R0139S) 
 HaeIII (NEB R0108S) 
 2X Syber Green Master Mix (Roche 04913914001 or Thermo Fisher A25742) 
 
-Genomic DNA must be column extracted for complete HhaI digest 
-Dilute genomic DNA to 10ng/ul; Need at least 20ul per run. 
-Always run 50% and 0% methylation controls 
-HaeIII is needed to control for melting differences due to different repeat lengths 
 
# RXNs x1 x 1 x 
Mock     Digest   
H2O 7.9  7.7  
Cutsmart 2  2  
HaeIII (20u/ul) 0.1  0.1  
HhaI (20u/ul) 0  0.2  
   10ul MM + 10ul DNA (100ng) 
37⁰ for 16hrs (overnight); 80⁰ for 20mins to inactivate enzymes 
qPCR with Syber Green 
CpG1: chr9:27574058-27574271; Primers: 5PC9 F + Out5PC9 R  
CpG2: chr9:27,573,299-27,573,429; Primers: 2CpG DIG F + 2CpG DIG R (always unmethylated) 
 
Reagent Amount (ul) 
2X Syber Green Mix 10 
5uM Primer F 1.2 
5uM Primer R 1.2 
milliH2O 5.1 
Digested DNA 2.5  
17.5ul MM + 2.5ul DNA (12.5ng/reaction) 
 
-Add MM to plate first in duplicates 
-Add DNA and seal plate 
-Run on Applied Biosystems Step One Plus qPCR machine (standard cycling for syber green 
reagents) 
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Chromatin immunoprecipitation from cell lines 
 
Solutions Needed: 
 1 M Tris-HCl pH 8 (6.05g for 50mL) 
 5 M NaCl (14.61g for 50mL) 
 0.5M EDTA (0.731g for 50mL) 
 Lysis Buffer (for 200mL): 0.5% SDS (10mL of 10% SDS), 10mM EDTA (0.584g), 50mM Tris/HCl pH 8 (1.21g) 
 ChiP dilution Buffer (for 200mL): 0.01% SDS (0.2mL of 10%), 1.1% TritonX (2.2mL), 1.2mM EDTA (0.07g), 16.7mM 
Tris/HCl pH 8 (0.40g), 167mM NaCl (1.95g) 
 Low Salt Buffer (for 50mL): 0.1% SDS (0.5mL of 10%), 1% TritonX (0.5mL), 1.2mM EDTA, 16.7mM Tris/HCl pH 8, 
150mM NaCl (0.44g) 
 High Salt Buffer (for 50mL): 0.1% SDS (0.5mL of 10%), 1% TritonX (0.5mL), 1.2mM EDTA, 16.7mM Tris/HCl pH 8, 
500mM NaCl (1.46g) 
 LiCl Buffer (for 50mL): 0.25M LiCl (0.53g), 1% NP-40 (0.5mL), 1% sodium deoxycholate (0.5g), 1mM EDTA (0.1mL of 
0.5M), 10mM Tris/HCl pH 8 (0.5mL of 1M) 
 Elution Buffer (for 50mL): 1% SDS (0.5mL), 50mM Tris/HCl pH 8 (2.5mL of 1M), 1mM EDTA (0.1mL of 0.5M) 
 BSA Blocking (for 50mL): 0.25g BSA, 1X PBS  
 
I) Lysate Preparation and Crosslinking 
1. Cells grown to 90% confluency in 10cm dishes (~8 million cells per dish) 
2. Crosslinking: Aspirate media and carefully add 10mL media with 1% formaldehyde; 
(270ul pf 37% formaldehyde stock per 10mL media) 
3. Incubate for 10 mins at 37 degrees 
4. Quench: Add 500μL 2.5 M Glycine  directly to cells and incubate for 10 mins at 37 to 
quench; color should change to yellow 
5. Add 10mL cold 1X PBS to wash cells; scrape cells with cell scrapper and add to cold 15mL 
conical 
6. Pellet cells at 2,000 rpm for 5 mins at 4 degrees; aspirate liquid 
7. Resuspend in 1.2mL cold ChIP lysis buffer (+ 1μL 1000X protease inhibitor)  
8. Transfer 400μL of the cells + lysis buffer to bioruptor tubes (~2x106 cells per tube) for 
sonication 
9. Freeze lysates at -80, or incubate 10 mins on ice and proceed directly to sonication 
10. Sonicate with bioruptor on high, 30 on, 30 off for 30 cycles total; After every 10 cycles, 
spin for 30 sec max seed (20,000g), 4⁰ and vortex briefly. 
11. After sonication, spin max speed for 10 mins, 4⁰; transfer and combine supernatant to 
new chilled tubes  
12. Take 100μL lysate from each sample for DNA analysis and freeze the remaining lysate at 
-80. 
13. Reverse cross-link the 100μL lysate by adding 2ul RNAse A (10mg/mL) and incubating at 
37 for 30 mins; next add 1 ul proteinase K (20mg/mL) and incubate ON at 65⁰  
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14. Isolate DNA from the 100μL lysate using Qiagen PCR purfication kit; elute in 50μL EB 
buffer and nanodrop; Run 1-2ug of DNA on gel to determine sheer size; Optimal shear is 
200-500bp. 
 
II) Beads Preparation 
Can use either agarose or Dyanabeads protein A 
1. Vortex and pipette beads to resuspend 
2. Add 30μL protein A beads/Dynabeads to 1.7mL tubes; one tube per IP or IgG control  
3. Wash beads 2X with 500μL 0.5% BSA blocking solution 
4. Resuspend in 50ul 0.5% BSA blocking solution 
5. Add antibody to IP tubes (5-10μL for cell signaling antibodies; varies depending on 
antibody) 
6. Add 2μl IgG (of 1.14 mg/mL stock or ~ 2μg)  
7. Incubate on rotator, 4⁰ for 5 hrs to overnight 
8. Wash beads 2X with 250ul block solution and resuspend in 50μL BSA blocking solution 
9. Dilute sonicated lysate with 5X ChiP dilution buffer; make enough for 20ug per IP/IgG 
reaction plus at least 10% extra 
10. Remove 10% of the volume of diluted lysate (2 μg DNA) for the input (one per sample), 
store at 4⁰ 
11. Add volume of lysate corresponding to 20ug DNA (same volume for IP and IgG samples) 
to the corresponding beads/antibody + BSA tubes 
12. Incubate ON on rotor at 4⁰ 
 
III) ChiP Washes and Reverse Cross-linking 
1. Pellet beads and discard supernatant 
2. Add 1mL Low-salt wash buffer, incubate on rotor for 10 mins at 4⁰ 
3. Pellet beads and discard supernatant; Add 1mL of High Salt buffer, incubate on rotor, 10 
min, 4⁰ 
4. Pellet beads and discard supernatant; Add 1mL of LiCl buffer, incubate on rotor, 10 min, 
4⁰ 
5. Pellet beads and discard supernatant; Add 1mL of 1X TE buffer, incubate on rotor, 10 
min, 4⁰ 
6. Spin briefly on microcentrifuge and place back on magnet to remove final bit of liquid 
7. Elute samples from beads by adding 200μL Elution buffer, incubate at 65⁰ for 20 min 
with shaking at 500rpm; flick tubes every 5 mins 
8. Pellet beads and collect supernatant in new tubes 
9. To inputs: add elution buffer to total 200ul 
10. Add 8ul of 10mg/ml RNAse A to each sample and incubate for 1 hour at 37⁰ 
11. Add 3μl Proteinase K (20mg/mL), 8 μL 1M Tris-HCl, 8 μL 5M NaCl and 8 μL 0.25M EDTA 
to all samples 
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12. Incubate ON at 65⁰  
13. Isolate DNA using Qiagen PCR purification kit; elute 2X with 50μL EB buffer 
14. Perform q-PCR (10μl 2X SyberGreen, 1.2μL each primer, 4μL DNA, 3.6μL H2O per 
reaction) 
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Feeder Free iPSC culture 
 
Coating Plates with Matrigel 
 Matrigel is aliquotted in 150ul and 300ul at -20 C 
 Thaw Matrigel for 30-45 mins at 4 C; Do not leave at RT 
 Add 150ul to a maximum of 12mL of cold DMEM/F12 media or 300ul to a max of 24mL 
media 
o Can make more concentrated if need fewer wells 
 Use cold pipet to transfer 1mL of media+matrigel to each well on a 6 well plate 
 Swirl plates to make sure wells are fully coated and incubate at RT for 45-60 mins 
 
Making mTeSR 1 Media 
 Combine 400mL Base media with 100mL Supplement to make complete mTeSR 1 media 
 Aliqout 25-50mL to keep at 4 C and wrap in foil to protect from light 
o Can be used for 2 weeks 
 Aliqout rest of media and freeze at -20 C  
o Stable for 6 months 
 
Thawing Cells 
 Make wash media: Mix 12.5 mL of DMEM/F12 media with 12.5 mL mTesR1 media 
 Let cells thaw in water bath 
 Thaw ROCK inhibitor  
 Add cells to 25mL of wash media 
 Spin at 1,2000 rpm for 3 mins (Program 1 -> Enter -> Start) 
 Vacuum off media from matrigel coated plates 
 Check for cell pellet and vacuum off media 
 Resuspend cells in 2mL mTesR1 media per well 
 Add 1ul ROCK inhibitor per 5mL media and mix by pipetting  
 Plate 2mL of cells per well 
 Mix plates before putting in incubator 
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Differentiation of iPSCs to NPCs 
 
Necessary reagents: 
Reagent Supplier Cat# 
2-Mercaptoethanol Fisher 21985-023 
B27 Supplement Cell Center (Invitrogen) 17504044 
 DMEM/F12 Cell Center (Invitrogen) 11320033 
Glutamax Supplement Cell Center (Invitrogen) 35050061 
Human FGF2 (Basic) PeproTech 100-18B 
N2 supplement Cell Center (Invitrogen) 17502048 
Neurobasal media Cell Center(Invitrogen) 21103049 
 Dorsomorphin Sigma P5499-5MG 
MEM non-essential amino acids Cell Center (Invitrogen) 11140050 
 L-Glutamine Cell Center (Invitrogen) 25030-024 
Insulin (human) Sigma (cell center)   I9278-5ML 
Pencillin/Streptomyocin Cell Center (Invitrogen) 15140122 
SB431542 Fisher (Tocris) 161410 
Matrigel Corning 354277 
ROCK inhibitor Y27632 ATCC ACS-3030 
Accutase StemCell Technologies 07920 
mTeSR1 StemCell Technologies 05850 
 
Media Recipes: 
 
  N-2 Media   
Component Stock Con. Final Con. 
DMEM/F12 1X 1X 
GlutaMAX 100X 1X 
N2 Supplement 100X 1X 
Insulin 11.2mg/mL 5ug/mL 
L-Glutamine 200mM 1mM 
non-essential amino acids 10mM 0.1mM 
2-Mercaptoethanol 55mM 0.1mM 
Pen/Strept 10,000mg/mL 50mg/mL 
      
  B-27 Media   
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Component Stock Con. Final Con. 
Neurobasal media 1X 1X 
B27 Supplement 50x 1X 
L-Glutamine 200mM 1mM 
Pen/Strep 10,000mg/mL 50mg/mL 
   
  
Neural Maintenance Media  (1:1 mix of N-2 
and B-27 media) 
Component Stock Con. Final Con. 
N-2 media 1X 1X 
B-27 Media 1X 1x 
   
  
Neural Induction Media - make fresh, lasts 5 
days 
Component Stock Con. Final Con. 
Neural maintenance Media 1X 1X 
SB431542  100mM 10uM 
Dorsomorphin 10mM 1uM 
     Neural Freezing media - make fresh 
Component Stock Con. Final Con. 
Neural Maintenance Media 1X 1X 
DMSO 100% 10% 
FGF-2 50ug/mL 0.02ug/mL 
 
Protocol: 
 
Day 0: Plating of iPSCs for Neural Induction 
 Grow iPSCs to confluency in 10cm dishes with Mtser1 
 Remove Mtser1 and add 4mL Accutase per 10 cm dish 
 Incubate at 37⁰ for 6-8 mins until cell lift off plate 
 Pipette up and down with a P1000 to break up clumps of cells, then add 4mL 
DMEM 
 Transfer to 15mL conical and pellet cells at 1,200 rpm for 3 mins 
 Resuspend cells in 8mL of Mtser + Rocki (10uM final con.)  
 Remove 50ul for counting and add to 50ul trypan blue; count cells 
 Seed cells at 2x106 cells/well in a 6 well plate coated with matrigel (Note: this is 
dependent on cell line; slowly growing lines may require higher density 
seeding; cells should be a confluent monolayer the next day) 
 
Day 1 – 6: Feed cells 
 Cells should be 100% confluent before beginning induction 
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 Prepare Neural Induction Media by adding SB431542 (10uM final con.) and 
Dorsomorphin (1uM final con.); Induction media should be prepared fresh every 
5 days 
 Remove media, wash with 1mL of DMEM to remove dead cells 
 Add 2mL Neural Induction Media 
 
Day 5: Passage #1 (1:2 split) 
 By day 5, the cells should be extremely confluent and may even start to lift off the 
plate 
 Remove media and wash with 1 mL DMEM  
 Add 1 mL accutase and incubate at 37⁰ for 6-8 mins or until cells detach 
 Add 1 mL DMEM and break up cell clumps with P1000 
 Pellet cells at 1,200 rpm for 3 mins 
 Resuspend in Neural Induction Media and seed into new matrigel coated 6 well 
dish; split cells 1:2, which will be ~1x10
6
 cells/well 
 
Day 6-7: Feed cells 
 Feed cells with Neural induction media 
 Cells should now undergo a morphological change to an epithelial like 
appearance (e.g. polygonal and large rather than the small and round iPSCs) 
 
Day 8: Passage #2 (1:3 or 1:2 split depending on cell line) 
 Cells should be confluent again by day 8 
 Repeat passaging as on day 5, but this time split 1:3 if they are a fast growing line 
or 1:2 if they grow more slowly 
 Wells can be pelleted for RNA extraction or used for seeding coverslips for IHC; 
Oct4 expression should be very low and Pax6 should be high in day 8 NPCs 
 
Day 9-11: Feed cells 
 Continue feeding with Neural Induction Media each day 
 Cells should now start to form neural rosettes structures, although they may not be 
well defined 
 
Day 12: Freezing of NPCs and switch to Neural Maintenance media  
 NPCs can now be frozen down and used for future expansion to neurons 
 Remove media and add 1mL accutase per well for 6-8 mins at 37⁰ 
 Add 1 mL media, pipette to break up clumps and transfer to conical tube 
 Spin 1,200 rpm for 3 mins; remove media 
 Resuspend in Neural Freezing media with freshly added FGF-2 and DMSO 
 Freeze 1 mL per cryovial in Mr. Freezy at -80; transfer to liquid nitrogen the next 
day  
 
Day 13-20: NPC Expansion – SWITCH to Laminin Matrix 
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 After day 12, add 20ng/mL FGF-2 to the media for the next 4 days to promote 
cell division of NPCs 
 After FGF-2 treatment, media can be changed every other day rather than every 
day 
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